

Grape King Bio Ltd.

**Parent Company Only Financial Statements for the
Years Ended December 31, 2025 and 2024 and
Independent Auditors' Report**

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
Grape King Bio Ltd.

Opinion

We have audited the accompanying parent company only financial statements of Grape King Bio Ltd. (the "Company"), which comprise the parent company only balance sheets as of December 31, 2025 and 2024, and the parent company only statements of comprehensive income, changes in equity and cash flows for the years ended then ended, and the notes to the parent company only financial statements, including material accounting policy information (collectively referred to as the "parent company only financial statements").

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the parent company only financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the parent company only financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matter of the Company's parent company only financial statements for the year ended December 31, 2025 is described as follows:

Revenue Recognition

Due to the significance and inherent risks of sales revenue recognition, and the associated risk of material misstatement, determining whether sales revenue from customers, meeting the specified criteria, was appropriately recognized under the established standards is a key audit matter. Relevant accounting policies are disclosed in Note 4 and Note 23 to the consolidated financial statements.

Our key audit procedures performed with respect to the above area included the following:

1. Understood and tested the design and operating effectiveness of relevant key internal controls;
2. Obtained details of sales revenue for customers meeting the specified criteria, sampled external orders, shipment acknowledgment forms, and other relevant external information, and verified the payment status to validate the authenticity of the revenue recognition.

Responsibilities of Management and Those Charged with Governance for the Parent Company Only Financial Statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion.

Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.


5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the Company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements for the year ended December 31, 2025 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Ming Yuan Chung and Chin Yuan Wen.



Deloitte & Touche
Taipei, Taiwan
Republic of China

March 4, 2026

Notice to Readers

The accompanying financial statements are intended only to present the financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and financial statements shall prevail.

GRAPE KING BIO LTD.

BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

ASSETS	2025		2024		LIABILITIES AND EQUITY	2025		2024	
	Amount	%	Amount	%		Amount	%	Amount	%
CURRENT ASSETS					CURRENT LIABILITIES				
Cash and cash equivalents (Note 6)	\$ 1,069,339	9	\$ 886,509	8	Contract liabilities (Note 20)	\$ 38,918	-	\$ 32,908	-
Notes and accounts receivable, net (Notes 9 and 20)	140,995	1	90,455	1	Notes and accounts payable	320,739	3	265,321	2
Accounts receivable from related parties (Notes 20 and 28)	207,385	2	294,841	2	Other payables (Note 17)	842,015	7	862,394	8
Other receivables (Note 9)	13,784	-	6,939	-	Other payables to related parties (Note 28)	4,020	-	1,716	-
Other receivables from related parties (Note 28)	74,040	1	83,879	1	Current tax liabilities (Note 22)	68,172	1	101,581	1
Inventories (Note 10)	694,597	6	664,424	6	Lease liabilities (Notes 13 and 28)	22,916	-	19,474	-
Other current assets (Notes 16 and 28)	24,554	-	14,775	-	Other current liabilities (Notes 17 and 28)	29,830	-	20,599	-
Total current assets	2,224,694	19	2,041,822	18	Total current liabilities	1,326,610	11	1,303,993	11
NON-CURRENT ASSETS					NON-CURRENT LIABILITIES				
Financial assets at amortized cost (Notes 8 and 29)	10,800	-	9,600	-	Deferred tax liabilities (Note 22)	88,530	1	82,253	1
Investments accounted for using the equity method (Note 11)	3,784,174	32	3,836,452	33	Lease liabilities (Notes 13 and 28)	78,787	1	88,051	1
Property, plant and equipment (Notes 12, 29 and 30)	5,336,374	45	5,168,057	45	Other non-current liabilities (Notes 17 and 28)	2,812	-	3,124	-
Right-of-use assets (Note 13)	99,258	1	106,227	1	Total non-current liabilities	170,129	2	173,428	2
Investment properties (Note 14)	233,103	2	233,370	2	Total liabilities	1,496,739	13	1,477,421	13
Intangible assets (Note 15)	70,473	-	70,554	1	EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Note 19)				
Deferred tax assets (Note 22)	284	-	284	-	Share capital				
Other non-current assets (Notes 16, 18 and 28)	79,408	1	66,754	-	Ordinary shares	1,481,374	12	1,481,374	13
Total non-current assets	9,613,874	81	9,491,298	82	Capital surplus	2,881,504	24	2,878,597	25
					Retained earnings				
					Legal reserve	1,812,438	16	1,678,017	14
					Special reserve	142,758	1	47,543	-
					Unappropriated earnings	4,047,691	34	4,004,929	35
					Total retained earnings	6,002,887	51	5,730,489	49
					Other equity	(23,936)	-	(34,761)	-
					Total equity	10,341,829	87	10,055,699	87
TOTAL	<u>\$ 11,838,568</u>	<u>100</u>	<u>\$ 11,533,120</u>	<u>100</u>	TOTAL	<u>\$ 11,838,568</u>	<u>100</u>	<u>\$ 11,533,120</u>	<u>100</u>

The accompanying notes are an integral part of the parent company only financial statements.

GRAPE KING BIO LTD.

STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2025		2024	
	Amount	%	Amount	%
NET REVENUE (Notes 20 and 28)	\$ 2,853,309	100	\$ 2,827,858	100
COST OF GOODS SOLD (Notes 10 and 21)	<u>(1,649,278)</u>	<u>(58)</u>	<u>(1,530,216)</u>	<u>(54)</u>
GROSS PROFIT	1,204,031	42	1,297,642	46
REALIZED GAIN ON TRANSACTIONS WITH SUBSIDIARIES AND ASSOCIATES	<u>(24,705)</u>	<u>(1)</u>	<u>1,116</u>	<u>-</u>
ADJUSTED GROSS PROFIT	<u>1,179,326</u>	<u>41</u>	<u>1,298,758</u>	<u>46</u>
OPERATING EXPENSES (Notes 18, 21 and 28)				
Selling and marketing	(406,289)	(14)	(401,242)	(14)
General and administrative	(366,011)	(13)	(403,674)	(15)
Research and development	<u>(239,325)</u>	<u>(8)</u>	<u>(256,578)</u>	<u>(9)</u>
Total operating expenses	<u>(1,011,625)</u>	<u>(35)</u>	<u>(1,061,494)</u>	<u>(38)</u>
INCOME FROM OPERATIONS	<u>167,701</u>	<u>6</u>	<u>237,264</u>	<u>8</u>
NON-OPERATING INCOME AND EXPENSES (Notes 11, 21 and 28)				
Interest income	8,580	-	10,548	-
Other income	84,719	3	101,274	4
Other gains and losses	1,056	-	4,103	-
Finance costs	(2,130)	-	(2,038)	-
Share of profit of subsidiaries and associates	<u>989,744</u>	<u>35</u>	<u>1,142,649</u>	<u>41</u>
Total non-operating income	<u>1,081,969</u>	<u>38</u>	<u>1,256,536</u>	<u>45</u>
PROFIT BEFORE INCOME TAX	1,249,670	44	1,493,800	53
INCOME TAX EXPENSE (Note 22)	<u>(31,365)</u>	<u>(1)</u>	<u>(45,501)</u>	<u>(2)</u>
NET PROFIT FOR THE YEAR	<u>1,218,305</u>	<u>43</u>	<u>1,448,299</u>	<u>51</u>
OTHER COMPREHENSIVE INCOME (LOSS) (Note 19)				
Items that will not be reclassified subsequently to profit or loss:				
Remeasurement of defined benefit plans	2,445	-	4,751	-
Unrealized loss on investments in equity instruments at fair value through other comprehensive income	-	-	(98)	-
Remeasurement of defined benefit plans for subsidiaries recognized using the equity method	270	-	453	-
Income tax relating to items that will not be reclassified subsequently to profit or loss	(543)	-	(1,041)	-

(Continued)

GRAPE KING BIO LTD.

STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2025		2024	
	Amount	%	Amount	%
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translating the financial statements of foreign operations	\$ 4,396	-	\$ 38,132	2
Exchange differences on translating the financial statements of foreign operations of associate	<u>6,429</u>	<u>-</u>	<u>6,772</u>	<u>-</u>
Other comprehensive income (loss) for the year, net of income tax	<u>12,997</u>	<u>-</u>	<u>48,969</u>	<u>2</u>
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	<u>\$ 1,231,302</u>	<u>43</u>	<u>\$ 1,497,268</u>	<u>53</u>
EARNINGS PER SHARE (Note 23)				
Basic earnings per share	<u>\$ 8.22</u>		<u>\$ 9.78</u>	
Diluted earnings per share	<u>\$ 8.17</u>		<u>\$ 9.71</u>	

The accompanying notes are an integral part of the parent company only financial statements.

(Concluded)

GRAPE KING BIO LTD.

**STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)**

	Share Capital - Ordinary Shares			Retained Earnings			Others		Total Equity
	Number of Shares (In Thousands)	Amount	Capital Surplus	Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translating the Financial Statements of Foreign Operations	Unrealized Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income	
BALANCE AT JANUARY 1, 2024	148,137	\$ 1,481,374	\$ 2,876,346	\$ 1,474,160	\$ 70,828	\$ 4,155,148	\$ (79,665)	\$ 108	\$ 9,978,299
Appropriation of 2023 and first half of 2024 earnings									
Legal reserve	-	-	-	203,857	-	(203,857)	-	-	-
Special reserve	-	-	-	-	(23,285)	23,285	-	-	-
Cash dividends	-	-	-	-	-	(1,422,119)	-	-	(1,422,119)
Change in other capital surplus	-	-	2,251	-	-	-	-	-	2,251
Net profit for the year ended December 31, 2024	-	-	-	-	-	1,448,299	-	-	1,448,299
Other comprehensive income (loss) for the year ended December 31, 2024, net of income tax	-	-	-	-	-	4,163	44,904	(98)	48,969
Total comprehensive income (loss) for the year ended December 31, 2024	-	-	-	-	-	1,452,462	44,904	(98)	1,497,268
Disposal of investments in equity instruments designated as at fair value through other comprehensive income	-	-	-	-	-	10	-	(10)	-
BALANCE AT DECEMBER 31, 2024	148,137	1,481,374	2,878,597	1,678,017	47,543	4,004,929	(34,761)	-	10,055,699
Appropriation of Earnings for the Second Half of 2024 and the First Half of 2025									
Legal reserve	-	-	-	134,421	-	(134,421)	-	-	-
Special reserve	-	-	-	-	95,215	(95,215)	-	-	-
Cash dividends	-	-	-	-	-	(948,079)	-	-	(948,079)
Change in ownership interests in subsidiary	-	-	721	-	-	-	-	-	721
Change in other capital surplus	-	-	2,186	-	-	-	-	-	2,186
Net profit for the year ended December 31, 2025	-	-	-	-	-	1,218,305	-	-	1,218,305
Other comprehensive income (loss) for the year ended December 31, 2025, net of income tax	-	-	-	-	-	2,172	10,825	-	12,997
Total comprehensive income (loss) for the year ended December 31, 2025	-	-	-	-	-	1,220,477	10,825	-	1,231,302
Disposal of investments in equity instruments designated as at fair value through other comprehensive income	-	-	-	-	-	-	-	-	-
BALANCE AT DECEMBER 31, 2025	148,137	\$ 1,481,374	\$ 2,881,504	\$ 1,812,438	\$ 142,758	\$ 4,047,691	\$ (23,936)	\$ -	\$ 10,341,829

The accompanying notes are an integral part of the parent company only financial statements.

GRAPE KING BIO LTD.

STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (In Thousands of New Taiwan Dollars)

	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	\$ 1,249,670	\$ 1,493,800
Adjustments for:		
Depreciation expenses	362,204	331,817
Amortization expenses	28,726	23,060
Expected credit loss recognized (reversed)	-	-
Net gain on financial assets at fair value through profit or loss	-	(192)
Finance costs	2,130	2,038
Interest income	(8,580)	(10,548)
Share of profit of subsidiaries and associates	(989,744)	(1,142,649)
Gain on disposal of property, plant and equipment, net	(160)	(30)
Gain on disposal of equity method investment	(315)	-
Gain on inventories on retirement and reversals	-	(4,468)
(Realized) unrealized gain on transactions with subsidiaries and associates	24,705	(1,116)
Unrealized loss (gain) on foreign currency exchange	197	(4,821)
Gain on modification of lease agreements	-	(1,179)
Changes in operating assets and liabilities		
Notes and accounts receivable, net	(50,338)	(29,088)
Accounts receivable from related parties	87,544	74,597
Other receivables	(17)	40
Other receivables from related parties	9,839	(4,485)
Inventories	(30,173)	(82,396)
Other current assets	(9,779)	3,745
Contract liabilities	6,010	8,984
Notes and accounts payable	55,406	26,826
Other payables	(78,606)	14,803
Other payables to related parties	2,304	1,116
Other current liabilities	9,231	14,233
Net defined benefit liabilities	(2,349)	(2,868)
Cash generated from operations	667,905	711,219
Interest received	8,580	10,548
Interest paid	(78)	(16)
Income tax paid	(65,814)	(139,830)
Net cash generated from operating activities	<u>610,593</u>	<u>581,921</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Proceeds from sale of financial assets at fair value through other comprehensive income	-	30
Acquisition of financial assets at amortized cost	(1,200)	-
Proceeds from redemption of financial assets at amortized cost	-	15,200
Acquisition of financial assets at fair value through profit or loss	-	(100,000)
Proceeds from sale of financial assets at fair value through profit or loss	-	100,192
loss	-	(Continued)

GRAPE KING BIO LTD.

STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (In Thousands of New Taiwan Dollars)

	2025	2024
Acquisition of equity-method investment	\$ (10,982)	\$ -
Disposal of investments accounted for using the equity method	315	-
Acquisition of property, plant and equipment	(392,716)	(585,309)
Proceeds from disposal of property, plant and equipment	160	30
Increase in refundable deposits	(530)	(325)
Decrease in refundable deposits	125	1,983
Acquisition of intangible assets	(17,989)	(19,945)
Other non-current assets increased	(20)	-
Dividends received	<u>1,040,061</u>	<u>987,006</u>
Net cash generated from investing activities	<u>617,224</u>	<u>398,862</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from long-term borrowings	-	-
Repayments of long-term borrowings	-	-
Proceeds from guarantee deposits received	102	1,579
Refund of guarantee deposits received	(414)	(2,172)
Repayment of the principal portion of lease liabilities	(24,271)	(22,626)
Dividends paid to owners of the Company	(1,022,148)	(1,022,148)
Other financing activities	<u>2,186</u>	<u>2,251</u>
Net cash used in financing activities	<u>(1,044,545)</u>	<u>(1,043,116)</u>
EFFECTS OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		
	<u>(442)</u>	<u>3,797</u>
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	182,830	(58,536)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	<u>886,509</u>	<u>945,045</u>
CASH AND CASH EQUIVALENTS, END OF YEAR	<u>\$ 1,069,339</u>	<u>\$ 886,509</u>

The accompanying notes are an integral part of the parent company only financial statements.

(Concluded)

GRAPE KING BIO LTD.

NOTES TO THE PARENT COMPANY ONLY FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

1. GENERAL INFORMATION

Grape King Bio Ltd. (the “Company”) was incorporated as a listed company limited by shares under the provisions of the Company Act, the Securities and Exchange Act and other related regulations of the Republic of China (“ROC”). In April 1971, the Company was officially registered as Grape King Food Limited and started its operations. In 1979, the Company merged with China Fuso Seiko Pharmaceutical Industries Ltd. and was renamed as Grape King Inc. In 1981, the Company further merged with Head Fancy Cosmetics Co. Ltd. The Company’s shares are listed and have been trading on the Taiwan Stock Exchange (TWSE) since December 1982. In the annual shareholders’ meeting held on June 12, 2002, the Company resolved to change its name to Grape King Bio Ltd. The Company is engaged in the production and sale of pharmaceutical preparations, patent medicine, liquid tonics, drinks, healthy food, etc. The Company’s registered office and main business location is at No. 402, Sec. 2, Jinling Rd., Pingzhen Dist., Taoyuan City 324, Taiwan, Republic of China.

The parent company only financial statements are presented in the Company’s functional currency, the New Taiwan dollar.

2. APPROVAL OF FINANCIAL STATEMENTS

The parent company only financial statements were approved by the Company’s Board of Directors and issued March 4, 2026.

3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS

- a. The IFRS Accounting Standards endorsed by the FSC for application starting from 2026.

New, Amended and Revised Standards and Interpretations	Effective Date Announced by IASB
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”	January 1, 2026
Annual Improvements to IFRS Accounting Standards - Volume 11	January 1, 2026
IFRS 17 “Insurance Contracts” (including the 2020 and 2021 amendments)	January 1, 2023

As of the date the parent company only financial statements were authorized for issue, the Company has assessed that the application of other standards and interpretations will not have a material impact on the Company’s financial position and financial performance.

- b. The IFRS Accounting Standards in issue but not yet endorsed and issued into effect by the FSC

<u>New, Amended and Revised Standards and Interpretations</u>	<u>Effective Date Announced by IASB (Note 1)</u>
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”	To be determined by IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027 (Note 2)
IFRS 19 “Subsidiaries without Public Accountability: Disclosures” (including the 2025 revisions)	January 1, 2027
Amendments to IAS 21 “Translation to a Hyperinflationary Presentation Currency”	January 1, 2027

Note 1: Unless stated otherwise, the above IFRSs Accounting Standards are effective for annual reporting periods beginning on or after their respective effective dates.

Note 2: On September 25, 2025, the FSC announced that IFRS 18 will take effect starting from January 1, 2028. Listed entities could elect to apply IFRS 18 for an earlier period after the endorsement of IFRS 18 by the FSC.

As of the date the parent company only financial statements were authorized for issue, the Company is continuously assessing other impacts of the above amended standards and interpretations on the Company’s financial position and financial performance and will disclose the relevant impact when the assessment is completed.

4. SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION

- a. Statement of compliance

The parent company only financial statements have been prepared in conformity with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IFRS Accounting Standards as endorsed and issued into effect by the FSC.

- b. Basis of preparation

The parent company only financial statements have been prepared on the historical cost basis except for financial instruments which are measured at fair value, and net defined benefit assets (liabilities) which are measured at the present value of the defined benefit obligation less the fair value of plan assets.

The fair value measurements, which are grouped into Levels 1 to 3 based on the degree to which the fair value measurement inputs are observable and based on the significance of the inputs to the fair value measurement in its entirety, are described as follows:

- 1) Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
- 2) Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for an asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- 3) Level 3 inputs are unobservable inputs for an asset or liability.

When preparing these parent company only financial statements, the Company used the equity method to account for its investments in subsidiaries and associates. In order for the amounts of the net profit for the year, other comprehensive income for the year and total equity in the parent company only financial statements to be the same with the amounts attributable to the owners of the Company in its consolidated financial statements, adjustments arising from the differences in accounting treatments between the parent company only basis and the consolidated basis were made to investments accounted for using the equity method, the share of profit or loss of subsidiaries and associates, remeasurement of defined benefit plans for subsidiaries recognized using the equity method and the related equity items, as appropriate, in these parent company only financial statements.

c. Classification of current and non-current assets and liabilities

Current assets include:

- Assets held primarily for the purpose of trading;
- Assets expected to be realized within 12 months after the reporting period; and
- Cash and cash equivalents unless the asset is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period.

Current liabilities include:

- Liabilities held primarily for the purpose of trading;
- Liabilities due to be settled within 12 months after the reporting period; and
- Liabilities for which the Company does not have the substantial right at the end of the reporting period to defer settlement for at least 12 months after the reporting period.

Assets and liabilities that are not classified as current are classified as non-current.

d. Foreign currencies

In preparing the financial statements, transactions in currencies other than the Company's functional currency (i.e., foreign currencies) are recognized at the rates of exchange prevailing at the dates of the transactions.

At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Exchange differences on monetary items arising from settlement or translation are recognized in profit or loss in the period in which they arise.

Non-monetary items measured at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when fair value was determined. Exchange differences arising from the retranslation of non-monetary items are included in profit or loss for the period except for exchange differences arising from the retranslation of non-monetary items in respect of which gains and losses are recognized directly in other comprehensive income; in which cases, the exchange differences are also recognized directly in other comprehensive income.

Non-monetary items that are measured at historical cost in a foreign currency are translated using the exchange rate at the date of the transaction (i.e., not retranslated).

e. Inventories

Inventories consist of raw materials, supplies, semi-finished goods and work in progress, finished goods and merchandises, and are stated at the lower of cost or net realizable value. Inventory write-downs are made by item, except where it may be appropriate to group similar or related items. The net realizable value is the estimated selling price of inventories less all estimated costs of completion and costs necessary to make the sale. Inventories are recorded at the weighted-average cost on the balance sheet date.

f. Investments in subsidiaries

The Company uses the equity method to account for its investments in subsidiaries.

A subsidiary is an entity that is controlled by the Company.

Under the equity method, an investment in a subsidiary is initially recognized at cost and adjusted thereafter to recognize the Company's share of the profit or loss and other comprehensive income of the subsidiary. The Company also recognizes the changes in the Company's share of equity of subsidiaries.

Changes in the Company's ownership interest in a subsidiary that do not result in the Company losing control of the subsidiary are accounted for as equity transactions. The Company recognizes directly in equity any difference between the carrying amount of the investment and the fair value of the consideration paid or received.

When the Company's share of loss of a subsidiary exceeds its interest in that subsidiary (which includes any carrying amount of the investment accounted for using the equity method and long-term interests that, in substance, form part of the Company's net investment in the subsidiary), the Company continues recognizing its share of further loss, if any.

Any excess of the cost of acquisition over the Company's share of the net fair value of the identifiable assets and liabilities of a subsidiary at the date of acquisition is recognized as goodwill, which is included within the carrying amount of the investment and is not amortized. Any excess of the Company's share of the net fair value of the identifiable assets and liabilities over the cost of acquisition is recognized immediately in profit or loss.

The Company assesses its investment for any impairment by comparing the carrying amount with the estimated recoverable amount as assessed based on the investee's financial statements as a whole. Impairment loss is recognized when the carrying amount exceeds the recoverable amount. If the recoverable amount of the investment subsequently increases, the Company recognizes a reversal of the impairment loss; the adjusted post-reversal carrying amount should not exceed the carrying amount that would have been recognized (net of amortization or depreciation) had no impairment loss been recognized in prior years. An impairment loss recognized on goodwill cannot be reversed in a subsequent period.

When the Company loses control of a subsidiary, it recognizes the investment retained in the former subsidiary at its fair value at the date when control is lost. The difference between the fair value of the retained investment plus any consideration received and the carrying amount of the previous investment at the date when control is lost is recognized as a gain or loss in profit or loss. Besides this, the Company accounts for all amounts previously recognized in other comprehensive income in relation to that subsidiary on the same basis as would be required had the Company directly disposed of the related assets or liabilities.

Profit or loss resulting from downstream transactions is eliminated in full only in the parent company only financial statements. Profit and loss resulting from upstream transactions and transactions between subsidiaries is recognized only in the parent company only financial statements and only to the extent of interests in the subsidiaries that are not related to the Company.

g. Investments in associates

An associate is an entity over which the Company has significant influence and which is neither a subsidiary nor an interest in a joint venture.

The Company uses the equity method to account for its investments in associates.

Under the equity method, investments in an associate are initially recognized at cost and adjusted thereafter to recognize the Company's share of the profit or loss and other comprehensive income of the associate. The Company also recognizes the changes in the Company's share of the equity of associates.

When the Company subscribes for additional new shares of an associate at a percentage different from its existing ownership percentage, the resulting carrying amount of the investment differs from the amount of the Company's proportionate interest in the associate. The Company records such a difference as an adjustment to investments with the corresponding amount charged or credited to capital surplus - changes in capital surplus from investments in associates accounted for using the equity method. If the Company's ownership interest is reduced due to its additional subscription of the new shares of the associate, the proportionate amount of the gains or losses previously recognized in other comprehensive income in relation to that associate is reclassified to profit or loss on the same basis as would be required had the investee directly disposed of the related assets or liabilities. When the adjustment should be debited to capital surplus, but the capital surplus recognized from investments accounted for using the equity method is insufficient, the shortage is debited to retained earnings.

The entire carrying amount of an investment is tested for impairment as a single asset by comparing its recoverable amount with its carrying amount. Any impairment loss recognized is not allocated to any asset that forms part of the carrying amount of the investment. Any reversal of that impairment loss is recognized to the extent that the recoverable amount of the investment subsequently increases.

When the Company transacts with its associate, profits and losses resulting from the transactions with the associate are recognized in the parent company only financial statements only to the extent of interests in the associate that are not related to the Company.

h. Property, plant and equipment

Property, plant and equipment are initially measured at cost and subsequently measured at cost less accumulated depreciation.

Property, plant and equipment in the course of construction are measured at cost. Cost includes professional fees and borrowing costs eligible for capitalization. Such assets are depreciated and classified to the appropriate categories of property, plant and equipment when completed and ready for their intended use.

Except for freehold land which is not depreciated, the depreciation of property, plant and equipment is recognized using the straight-line method. Each significant part is depreciated separately. If their respective lease terms are shorter than their useful lives, such assets are depreciated over their lease terms. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each reporting period, with the effects of any changes in the estimates accounted for on a prospective basis.

On derecognition of an item of property, plant and equipment, the difference between the sales proceeds and the carrying amount of the asset is recognized in profit or loss.

i. Investment properties

Investment properties are properties held to earn rental and/or for capital appreciation. Investment properties also include land held for a currently undetermined future use.

Investment properties are initially measured at cost, including transaction costs. Subsequent to initial recognition, investment properties are measured at cost less accumulated depreciation.

For a transfer of classification from investment properties to property, plant and equipment, the deemed cost of the property for subsequent accounting is its carrying amount at the commencement of owner-occupation.

On derecognition of an investment property, the difference between the net disposal proceeds and the carrying amount of the asset is included in profit or loss.

j. Intangible assets

1) Intangible assets acquired separately

Intangible assets with finite useful lives that are acquired separately are initially measured at cost and subsequently measured at cost less accumulated amortization and accumulated impairment loss. Amortization is recognized on a straight-line basis. The estimated useful lives, residual values, and amortization methods are reviewed at the end of each reporting period, with the effect of any changes in the estimates accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are measured at cost less accumulated impairment loss.

2) Derecognition of intangible assets

On derecognition of an intangible asset, the difference between the net disposal proceeds and the carrying amount of the asset is recognized in profit or loss.

k. Impairment of property, plant and equipment, right-of-use asset, investment properties and intangible assets

At the end of each reporting period, the Company reviews the carrying amounts of its property, plant and equipment, right-of-use assets, investment properties and intangible assets, excluding goodwill, to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss. When it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. Corporate assets are allocated to the smallest group of cash-generating units on a reasonable and consistent basis of allocation.

The recoverable amount is the higher of fair value less costs to sell and value in use. If the recoverable amount of an asset or cash-generating unit is estimated to be less than its carrying amount, the carrying amount of the asset or cash-generating unit is reduced to its recoverable amount, with the resulting impairment loss recognized in profit or loss.

When an impairment loss is subsequently reversed, the carrying amount of the corresponding asset, or cash-generating unit is increased to the revised estimate of its recoverable amount, but only to the extent of the carrying amount that would have been determined had no impairment loss been recognized on the asset or cash-generating unit in prior years. A reversal of an impairment loss is recognized in profit or loss.

1. Financial instruments

Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities (other than financial assets and financial liabilities at FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in profit or loss.

1) Financial assets

All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis.

a) Measurement categories

Financial assets are classified into the following categories: financial assets at amortized cost and investments in equity instruments at FVTOCI.

i. Financial assets at FVTPL

Financial assets are classified as at FVTPL when such financial assets are mandatorily classified or designated as at FVTPL. Financial assets mandatorily classified as at FVTPL include investments in equity instruments which are not designated as at FVTOCI.

Financial assets at FVTPL are subsequently measured at fair value, and any remeasurement gains or losses on such financial assets are recognized in other gains or losses. Fair value is determined in the manner described in Note 27.

ii. Financial assets at amortized cost

Financial assets that meet the following conditions are subsequently measured at amortized cost:

- i) The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and
- ii) The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Subsequent to initial recognition, financial assets at amortized cost, including cash and cash equivalents, financial assets at amortized cost, notes and accounts receivable (net) (related parties included) and other receivables (related parties included) at amortized cost, are measured at amortized cost, which equals the gross carrying amount determined using the effective interest method less any impairment loss. Exchange differences are recognized in profit or loss.

Interest income is calculated by applying the effective interest rate to the gross carrying amount of such a financial asset, except for:

- i) Purchased or originated credit-impaired financial assets, for which interest income is calculated by applying the credit adjusted effective interest rate to the amortized cost of such financial assets; and

- ii) Financial assets that are not credit impaired on purchase or origination but have subsequently become credit impaired, for which interest income is calculated by applying the effective interest rate to the amortized cost of such financial assets in subsequent reporting periods.

A financial asset is credit impaired when one or more of the following events have occurred:

- i) Significant financial difficulty of the issuer or the borrower;
- ii) Breach of contract, such as a default;
- iii) It is becoming probable that the borrower will enter bankruptcy or undergo a financial reorganization; or
- iv) The disappearance of an active market for that financial asset because of financial difficulties.

Cash equivalents include time deposits with original maturities within 3 months from the date of acquisition, which are highly liquid, readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value. These cash equivalents are held for the purpose of meeting short-term cash commitments.

iii. Investments in equity instruments at FVTOCI

On initial recognition, the Company may make an irrevocable election to designate investments in equity instruments as at FVTOCI. Designation as at FVTOCI is not permitted if the equity investment is held for trading or if it is contingent consideration recognized by an acquirer in a business combination.

Investments in equity instruments at FVTOCI are subsequently measured at fair value with gains and losses arising from changes in fair value recognized in other comprehensive income and accumulated in other equity. The cumulative gain or loss will not be reclassified to profit or loss on disposal of the equity investments; instead, it will be transferred to retained earnings.

Dividends on these investments in equity instruments are recognized in profit or loss when the Company's right to receive the dividends is established, unless the dividends clearly represent a recovery of part of the cost of the investment.

b) Impairment of financial assets

The Company recognizes a loss allowance for expected credit losses on financial assets at amortized cost (including accounts receivable) and investments in debt instruments that are measured at FVTOCI.

The Company always recognizes lifetime expected credit losses (ECLs) for accounts receivable. For all other financial instruments, the Company recognizes lifetime ECLs when there has been a significant increase in credit risk since initial recognition. If, on the other hand, the credit risk on a financial instrument has not increased significantly since initial recognition, the Company measures the loss allowance for that financial instrument at an amount equal to 12-month ECLs.

Expected credit losses reflect the weighted average of credit losses with the respective risks of default occurring as the weights. Lifetime ECLs represent the expected credit losses that will result from all possible default events over the expected life of a financial instrument. In contrast, 12-month ECLs represent the portion of lifetime ECLs that is expected to result from

default events on a financial instrument that are possible within 12 months after the reporting date.

For internal credit risk management purposes, the Company determines that internal or external information which shows that the debtor is unlikely to pay its creditors would indicate that a financial asset is in default (without taking into account any collateral held by the Company).

The impairment loss of all financial assets is recognized in profit or loss by a reduction in their carrying amounts through a loss allowance account.

c) Derecognition of financial assets

The Company derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party.

On derecognition of a financial asset at amortized cost in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognized in profit or loss. However, on derecognition of an investment in an equity instrument at FVTOCI, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognized in profit or loss, and the cumulative gain or loss which had been recognized in other comprehensive income is transferred directly to retained earnings, without recycling through profit or loss.

2) Equity instruments

Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs.

The repurchase of the Company's own equity instruments is recognized in and deducted directly from equity. No gain or loss is recognized in profit or loss on the purchase, sale, issuance or cancellation of the Company's own equity instruments.

3) Financial liabilities

a) Subsequent measurement

All financial liabilities are measured at amortized cost using the effective interest method.

b) Derecognition of financial liabilities

The difference between the carrying amount of a financial liability derecognized and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss.

m. Provisions

Provisions are measured at the best estimate of the discounted cash flows of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

n. Revenue recognition

The Company identifies contracts with customers, allocates the transaction price to the performance obligations and recognizes revenue when performance obligations are satisfied.

1) Revenue from the sale of goods

Revenue from the sale of goods comes from sales of health food, beverages and cosmetics. Sales of health food, beverages and cosmetics are recognized as revenue when the goods are delivered to the customer's specific location because it is the time when the customer has full discretion over the manner of distribution and price to sell the goods, has the primary responsibility for sales to future customers and bears the risks of obsolescence. Trade receivables are recognized concurrently. For sales of health food, beverages and cosmetics through its own retail outlets, revenue is recognized when the customer purchases the goods at the retail outlet. For internet sales of health food, beverages and cosmetics, revenue is recognized when the goods are delivered to the customer's specific location. When the customer initially purchases the goods online, the transaction price received is recognized as a contract liability until the goods have been delivered to the customer.

2) Revenue from the rendering of services

Revenue from the rendering of services comes from ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) services.

As the Company provides ODM/OEM services, customers simultaneously receive and consume the benefits provided by the Company's satisfaction performance obligations. Consequently, the related revenue is recognized when services are rendered.

o. Leases

At the inception of a contract, the Company assesses whether the contract is, or contains, a lease.

1) The Company as lessor

Leases are classified as finance leases whenever the terms of a lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

Lease payments from operating leases are recognized as income on a straight-line basis over the terms of the relevant leases.

2) The Company as lessee

The Company recognizes right-of-use assets and lease liabilities for all leases at the commencement date of a lease, except for short-term leases and low-value asset leases accounted for applying a recognition exemption where lease payments are recognized as expenses on a straight-line basis over the lease terms.

Right-of-use assets are initially measured at cost, which comprises the initial measurement of lease liabilities adjusted for lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs needed to restore the underlying assets, and less any lease incentives received. Right-of-use assets are subsequently measured at cost less accumulated depreciation and impairment losses and adjusted for any remeasurement of the lease liabilities. Right-of-use assets are presented on a separate line in the consolidated balance sheets.

Right-of-use assets are depreciated using the straight-line method from the commencement dates to the earlier of the end of the useful lives of the right-of-use assets or the end of the lease terms.

Lease liabilities are initially measured at the present value of the lease payments. The lease payments are discounted using the interest rate implicit in a lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses the lessee's incremental borrowing rate.

Subsequently, lease liabilities are measured at amortized cost using the effective interest method, with interest expense recognized over the lease terms. When there is a change in a lease term resulting from a change in an index or a rate used to determine those payments, the Company remeasures the lease liabilities with a corresponding adjustment to the right-of-use-assets. However, if the carrying amount of the right-of-use assets is reduced to zero, any remaining amount of the remeasurement is recognized in profit or loss. For a lease modification that is not accounted for as a separate lease, the Company accounts for the remeasurement of the lease liability by (a) decreasing the carrying amount of the right-of-use asset of lease modifications that decreased the scope of the lease, and recognizing in profit or loss any gain or loss on the partial or full termination of the lease; (b) making a corresponding adjustment to the right-of-use asset of all other lease modifications. Lease liabilities are presented on a separate line in the balance sheets. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the periods in which they are incurred.

p. Borrowing costs

Borrowing costs are recognized in profit or loss in the period in which they are incurred.

q. Government grants

Government grants are not recognized until there is reasonable assurance that the Group will comply with the conditions attached to them and that the grants will be received.

Government grants related to income are recognized in other income on a systematic basis over the periods in which the Group recognizes as expenses the related costs that the grants intend to compensate.

Government grants that are receivable as compensation for expenses or losses already incurred are recognized in profit or loss in the period in which they are received.

r. Employee benefits

1) Short-term employee benefits

Liabilities recognized in respect of short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in exchange for the related services.

2) Retirement benefits

Payments to defined contribution retirement benefit plans are recognized as expenses when employees have rendered services entitling them to the contributions.

Defined benefit costs (including service cost, net interest and remeasurement) under defined benefit retirement benefit plans are determined using the projected unit credit method. Service cost (including current service cost) and net interest on the net defined benefit liabilities (assets) are recognized as employee benefits expense in the period in which they occur. Remeasurement, comprising actuarial gains and losses and the return on plan assets (excluding interest), is recognized in other comprehensive income in the period in which it occurs. Remeasurement recognized in other comprehensive income is reflected immediately in retained earnings and will not be reclassified to profit or loss.

Net defined benefit liabilities (assets) represent the actual deficit (surplus) in the Company's defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any refunds from the plans or reductions in future contributions to the plans.

s. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

1) Current tax

Income tax payable (refundable) is based on taxable profit (loss) for the year determined according to the applicable tax laws of each tax jurisdiction.

According to the Income Tax Law Act of the ROC, an additional tax on unappropriated earnings is provided for in the year the shareholders approve to retain earnings.

Adjustments of prior years' tax liabilities are added to or deducted from the current year's tax provision.

2) Deferred tax

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities and the corresponding tax bases used in the computation of taxable profit.

Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized.

Deferred tax liabilities are recognized for taxable temporary differences associated with investments in subsidiaries and associates, except where the Company is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interests are recognized only to the extent that it is probable that there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the assets to be recovered. A previously unrecognized deferred tax asset is also reviewed at the end of each reporting period and recognized to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liabilities are settled or the assets are realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. If investment properties measured using the fair value model are non-depreciable assets, or are held under a business model whose objective is not to consume substantially all of the economic benefits embodied in the assets over time, the carrying amounts of such assets are presumed to be recovered entirely through sale.

3) Current and deferred taxes

Current and deferred taxes are recognized in profit or loss, except when they relate to items that are recognized in other comprehensive income or directly in equity; in which case, the current and deferred taxes are also recognized in other comprehensive income or directly in equity, respectively.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Company's accounting policies, management is required to make judgments, estimations, and assumptions on the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered relevant. Actual results may differ from these estimates.

When developing material accounting estimates, the Company considers the possible impact on other relevant material estimates. The estimates and underlying assumptions are reviewed on an ongoing basis.

Material Accounting Judgements

a. Lease terms

In determining a lease term, the Company considers all facts and circumstances that create an economic incentive to exercise or not to exercise an option, including any expected changes in facts and circumstances from the commencement date until the exercise date of the option. Main factors considered include contractual terms and conditions for the optional periods, significant leasehold improvements undertaken over the contract term, the importance of the underlying asset to the lessee's operations, etc. The lease term is reassessed if a significant change in circumstances that are within control of the Company occurs.

Key Sources of Estimation Uncertainty

a. Estimated impairment of financial assets

The provision for impairment of trade receivables is based on assumptions about risk of default and expected loss rates. The Company uses judgment in making these assumptions and in selecting the inputs to the impairment calculation, based on the Company's historical experience, existing market conditions as well as forward looking estimates as of the end of each reporting period. For details of the key assumptions and inputs used, see Note 9. Where the actual future cash inflows are less than expected, a material impairment loss may arise.

b. Write-down of inventories

The net realizable value of inventories is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. The estimation of net realizable value is based on current market conditions and historical experience with product sales of a similar nature. Changes in market conditions may have a material impact on the estimation of the net realizable value.

c. Recognition and measurement of defined benefit plans

The net defined benefit liabilities (assets) and the resulting defined benefit costs under the defined benefit pension plans are calculated using the projected unit credit method. Actuarial assumptions comprise the discount rates, rates of employee turnover, future salary increases, etc. Changes in economic circumstances and market conditions will affect these assumptions and may have a material impact on the amount of related expenses and liabilities.

d. Lessee's incremental borrowing rates

In determining a lessee's incremental borrowing rate used in discounting lease payments, a risk-free rate for the same currency and relevant duration is selected as a reference rate, and the lessee's credit spread adjustments and lease specific adjustments (such as asset type, secured position, etc.) are also taken into account.

6. CASH AND CASH EQUIVALENTS

	December 31	
	2025	2024
Cash on hand	\$ 242	\$ 283
Deposits in banks		
Demand deposits	634,516	516,547
Checking accounts	8	8
Cash equivalents (investments with original maturities of less than 3 months)		
Repurchase agreements collateralized by bonds	400,000	350,000
Time deposits	<u>34,573</u>	<u>19,671</u>
	<u>\$ 1,069,339</u>	<u>\$ 886,509</u>

7. FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

The Company acquired ordinary shares of Hsin Tung Yang Co., Ltd. for medium to long-term strategic purposes. Accordingly, the management elected to designate these investments in equity instruments as at FVTOCI as they believe that recognizing short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Company's strategy of holding these investments for long-term purposes.

In July 2024, the Company sold ordinary shares of Hsin Tung Yang Co., Ltd. for \$30 thousand, and the unrealized gain on financial assets at FVTOCI of \$10 thousand was transferred to unappropriated earnings.

Financial assets at fair value through other comprehensive income were not pledged.

8. FINANCIAL ASSETS AT AMORTIZED COST

	December 31	
	2025	2024
<u>Non-current</u>		
Pledged time deposits	<u>\$ 10,800</u>	<u>\$ 9,600</u>

Refer to Note 27 for information relating to the credit risk management and impairment of investments in financial assets at amortized cost.

Refer to Note 29 for information relating to investments in financial assets at amortized cost pledged as security.

9. NOTES AND ACCOUNTS RECEIVABLE, NET AND OTHER RECEIVABLES

	<u>December 31</u>	
	<u>2025</u>	<u>2024</u>
<u>Notes receivable (a)</u>		
Notes receivable - operating	\$ <u>377</u>	\$ <u>8</u>
<u>Accounts receivable (a)</u>		
At amortized cost		
Gross carrying amount	140,618	90,447
Less: Loss allowance	<u>-</u>	<u>-</u>
	<u>140,618</u>	<u>90,447</u>
	<u>\$ 140,995</u>	<u>\$ 90,455</u>
<u>Other receivables (b)</u>		
Tax refund receivable	\$ 13,370	\$ 6,542
Other receivables	414	397
Less: Loss allowance	<u>-</u>	<u>-</u>
	<u>\$ 13,784</u>	<u>\$ 6,939</u>

a. Notes and accounts receivable

Some of the Company's customers use cash (or credit card) to settle payment; other than the customers who pay by cash (or credit card), the average credit period of sales of goods was 30-135 days. The Company adopted a policy of only dealing with entities that have passed internal credit assessment and obtaining sufficient collateral, where appropriate, as a means of mitigating the risk of financial loss from default.

In order to minimize credit risk, the management of the Company has delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, the Company reviews the recoverable amount of each individual trade debt at the end of the reporting period to ensure that adequate allowance is made for possible irrecoverable amounts. In this regard, the management believes the Company's credit risk was significantly reduced.

The Company measures the loss allowance for notes and accounts receivable at an amount equal to lifetime ECLs. The expected credit losses on notes and accounts receivable are estimated using a provision matrix by reference to the past default records of the debtor and an analysis of the debtor's current financial position, adjusted for general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as the forecasted direction of economic conditions at the reporting date. As the Company's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished according to the Company's different customer base.

Aging analysis of notes and accounts receivable (net) held by the Company was as follows:

	Neither Past Due nor Impaired	Past Due but not Impaired			Total
		Within 90 Days	91 to 180 Days	Over 180 Days	
December 31, 2025	\$ 136,834	\$ 4,161	\$ -	\$ -	\$ 140,995
December 31, 2024	83,766	6,686	3	-	90,455

Notes and accounts receivable were not pledged.

b. Other receivables

The Company measures the loss allowance for other receivables at an amount equal to the actual credit losses of customers; therefore, there is no uncertain recovery in addition to the amount as follows.

10. INVENTORIES

	December 31	
	2025	2024
Finished goods	\$ 232,139	\$ 222,373
Semi-finished goods and work in progress	246,808	234,638
Raw materials	152,123	143,409
Supplies	63,452	63,922
Merchandise	<u>75</u>	<u>82</u>
	<u>\$ 694,597</u>	<u>\$ 664,424</u>

The nature of the cost of goods sold is as follows:

	For the Year Ended December 31	
	2025	2024
Cost of inventories sold	<u>\$ 1,649,278</u>	<u>\$ 1,530,216</u>
Loss on retirement	<u>\$ 10,809</u>	<u>\$ 9,131</u>
Inventory write-downs (reversals)	<u>\$ -</u>	<u>\$ (4,468)</u>
Gain from physical counts	<u>\$ (1,015)</u>	<u>\$ (2,488)</u>

Inventories were not pledged.

11. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

	December 31	
	2025	2024
Investments in subsidiaries	\$ 3,670,682	\$ 3,758,851
Investments in associates	<u>113,492</u>	<u>77,601</u>
	<u>\$ 3,784,174</u>	<u>\$ 3,836,452</u>

a. Investments in subsidiaries

	December 31	
	2025	2024
Pro-partner Ltd. (Pro-partner)	\$ 2,441,862	\$ 2,514,568
GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI) (GKBVI)	1,166,446	1,186,542
Rivershine Ltd. (Rivershine)	52,187	57,741
MYGK BIO SDN.BHD (MYGK BIO)	<u>10,187</u>	<u>-</u>
	<u>\$ 3,670,682</u>	<u>\$ 3,758,851</u>
	Proportion of Ownership and Voting Rights	
	December 31	
Name of subsidiaries	2025	2024
Pro-partner	60%	60%
GKBVI	100%	100%
Rivershine	100%	100%
MYGK BIO	100%	-

Investments accounted for using the equity method were not pledged.

b. Investments in associates

	December 31	
	2025	2024
<u>Associate that are not individually material</u>		
GK BIO INTERNATIONAL SDN. BHD.	<u>\$ 113,492</u>	<u>\$ 77,601</u>

Aggregate information of associates that are not individually material.

	For the Year Ended December 31	
	2025	2024
The Company's share of:		
Net income	\$ 29,065	\$ 22,440
Other comprehensive income (loss)	<u>6,429</u>	<u>6,772</u>
Total comprehensive income	<u>\$ 35,494</u>	<u>\$ 29,212</u>

The Company had neither contingent liabilities nor capital commitments to the associate as of December 31, 2025 and 2024.

Investments in associates were not pledged.

12. PROPERTY, PLANT AND EQUIPMENT

	December 31	
	2025	2024
Assets used by the Company	<u>\$ 5,336,374</u>	<u>\$ 5,168,057</u>

a. Assets used by the Company

For the Year Ended December 31, 2025					
<u>Cost</u>	Balance at Beginning of Year	Additions	Disposals	Reclassification	Balance at End of Year
Land	\$ 1,522,723	\$ -	\$ -	\$ -	\$ 1,522,723
Land improvements	3,264	-	-	-	3,264
Buildings	3,818,839	3,191	(90)	16,488	3,838,428
Machinery and equipment	2,023,168	39,754	(27,266)	28,857	2,064,513
Transportation equipment	24,277	160	(300)	-	24,137
Leasehold improvements	17,998	150	-	-	18,148
Other equipment	362,292	30,856	(13,509)	27,253	460,982
Construction in progress	<u>161,822</u>	<u>403,211</u>	<u>-</u>	<u>(43,032)</u>	<u>522,001</u>
	<u>7,934,383</u>	<u>\$ 477,322</u>	<u>\$ (41,165)</u>	<u>\$ 29,566</u>	<u>8,400,106</u>
 <u>Accumulated depreciation</u>					
Land	-	\$ -	\$ -	\$ -	-
Land improvements	2,673	141	-	-	2,814
Buildings	1,120,264	153,214	(90)	-	1,273,388
Machinery and equipment	1,310,401	156,434	(27,266)	-	1,439,569
Transportation equipment	13,238	2,539	(300)	-	15,477
Leasehold improvements	17,998	25	-	-	18,023
Other equipment	<u>301,752</u>	<u>26,218</u>	<u>(13,509)</u>	<u>-</u>	<u>314,461</u>
	<u>2,766,326</u>	<u>\$ 338,571</u>	<u>\$ (41,165)</u>	<u>\$ -</u>	<u>3,063,732</u>
Carrying amount at December 31, 2025	<u>\$ 5,168,057</u>				<u>\$ 5,336,374</u>
 For the Year Ended December 31, 2024					
<u>Cost</u>	Balance at Beginning of Year	Additions	Disposals	Reclassification	Balance at End of Year
Land	\$ 1,522,723	\$ -	\$ -	\$ -	\$ 1,522,723
Land improvements	3,264	-	-	-	3,264
Buildings	3,443,526	7,420	(2,172)	370,065	3,818,839
Machinery and equipment	1,685,098	23,650	(11,568)	325,988	2,023,168
Transportation equipment	16,790	4,739	(1,719)	4,467	24,277
Leasehold improvements	17,998	-	-	-	17,998
Other equipment	349,541	17,096	(10,059)	5,714	362,292
Construction in progress	<u>380,628</u>	<u>429,235</u>	<u>-</u>	<u>(648,041)</u>	<u>161,822</u>
	<u>7,419,568</u>	<u>\$ 482,140</u>	<u>\$ (25,518)</u>	<u>\$ 58,193</u>	<u>7,934,383</u>
 <u>Accumulated depreciation</u>					
Land	-	\$ -	\$ -	\$ -	-
Land improvements	2,510	163	-	-	2,673
Buildings	983,908	138,528	(2,172)	-	1,120,264
Machinery and equipment	1,187,084	134,885	(11,568)	-	1,310,401
Transportation equipment	13,650	1,307	(1,719)	-	13,238
Leasehold improvements	17,998	-	-	-	17,998
Other equipment	<u>276,581</u>	<u>35,230</u>	<u>(10,059)</u>	<u>-</u>	<u>301,752</u>
	<u>2,481,731</u>	<u>\$ 310,113</u>	<u>\$ (25,518)</u>	<u>\$ -</u>	<u>2,766,326</u>
Carrying amount at December 31, 2024	<u>\$ 4,937,837</u>				<u>\$ 5,168,057</u>

The significant parts of the Company's buildings include main plants, air conditioning, electrical and wastewater treatment equipment and decoration, and the related depreciation is calculated based on the economic lives as below:

Significant Part of Buildings	Estimated Economic Lives
Main plant	30 to 60 years
Air conditioning and electrical	5 to 22 years
Wastewater treatment equipment	10 to 15 years
Decoration	15 years

No impairment assessment was performed for the years ended December 31, 2025 and 2024 as there was no indication of impairment.

Property, plant and equipment pledged as collateral for bank borrowings are set out in Note 29.

13. LEASE ARRANGEMENTS

a. Right-of-use assets

	December 31	
	2025	2024
<u>Carrying amounts</u>		
Land	\$ 46,277	\$ 46,936
Buildings	48,745	54,088
Transportation equipment	3,232	4,864
Other equipment	<u>1,004</u>	<u>339</u>
	<u>\$ 99,258</u>	<u>\$ 106,227</u>
	For the Year Ended December 31	
	2025	2024
Additions to right-of-use assets	<u>\$ 16,397</u>	<u>\$ 1,121</u>
Depreciation charge for right-of-use assets		
Land	\$ 2,301	\$ 2,255
Buildings	18,725	16,030
Transportation equipment	2,062	2,537
Other equipment	<u>278</u>	<u>616</u>
	<u>\$ 23,366</u>	<u>\$ 21,438</u>

b. Lease liabilities

	December 31	
	2025	2024
<u>Carrying amounts</u>		
Current	<u>\$ 22,916</u>	<u>\$ 19,474</u>
Non-current	<u>\$ 78,787</u>	<u>\$ 88,051</u>

Range of discount rates for lease liabilities was as follows:

	December 31	
	2025	2024
Land	1.84%-1.96%	1.02%-1.84%
Buildings	1.02%-1.96%	1.02%-1.80%
Transportation equipment	1.02%-1.96%	1.02%-1.84%
Other equipment	1.02%-1.96%	1.02%-1.84%

c. Material lease-in activities and terms

The Company leases certain land, buildings and transportation equipment with lease terms of 3 to 35 years. Lease payments for the lease contract of land will be adjusted on the basis of changes in announced land value prices. The Company does not have bargain purchase options to acquire the leasehold land and buildings at the end of the lease terms.

d. Other lease information

	For the Year Ended December 31	
	2025	2024
Expenses relating to short-term and low-value asset leases	<u>\$ 1,915</u>	<u>\$ 6,530</u>
Total cash outflow for leases	<u>\$ (29,186)</u>	<u>\$ (29,156)</u>

The Company leases certain land, transportation equipment and other equipment which qualify as short-term leases and low-value asset leases. The Company has elected to apply the recognition exemption and thus did not recognize right-of-use assets and lease liabilities for these leases.

14. INVESTMENT PROPERTIES

	Land	Buildings	Total
<u>Cost</u>			
Balance at January 1 and December 31, 2025	<u>\$ 224,988</u>	<u>\$ 12,250</u>	<u>\$ 237,238</u>
<u>Accumulated depreciation</u>			
Balance at January 1, 2025	\$ -	\$ 3,868	\$ 3,868
Depreciation expenses	<u>-</u>	<u>267</u>	<u>267</u>
Balance at December 31, 2025	<u>\$ -</u>	<u>\$ 4,135</u>	<u>\$ 4,135</u>
Carrying amount at December 31, 2025	<u>\$ 224,988</u>	<u>\$ 8,115</u>	<u>\$ 233,103</u>
<u>Cost</u>			
Balance at January 1 and December 31, 2024	<u>\$ 224,988</u>	<u>\$ 12,250</u>	<u>\$ 237,238</u>
<u>Accumulated depreciation</u>			
Balance at January 1, 2024	\$ -	\$ 3,602	\$ 3,602
Depreciation expenses	<u>-</u>	<u>266</u>	<u>266</u>
Balance at December 31, 2024	<u>\$ -</u>	<u>\$ 3,868</u>	<u>\$ 3,868</u>
Carrying amount at December 31, 2024	<u>\$ 224,988</u>	<u>\$ 8,382</u>	<u>\$ 233,370</u>

The investment properties are leased out for 5 years. The lease contracts contain market review clauses in the event that the lessees exercise their options to extend. The lessees do not have bargain purchase options to acquire the investment properties at the expiry of the lease periods.

The maturity analysis of lease payments receivable under operating leases of investment properties as of December 31, 2025 and 2024 is as follows:

	December 31	
	2025	2024
Year 1	\$ -	\$ 2,832
Year 2	<u>-</u>	<u>-</u>
	<u>\$ -</u>	<u>\$ 2,832</u>

Except for depreciation recognized, the Company did not have significant addition, disposal, or impairment of investment properties during the years ended December 31, 2025 and 2024. Investment properties are depreciated using the straight-line method over their estimated useful lives of 35 to 50 years.

Investment properties held by the Company are not measured at fair value; the fair value information below is for reference only. The determination of fair value was not performed by independent qualified professional valuers. The valuation was arrived at by reference to announced land value prices and market evidence of transaction prices for similar properties.

	December 31	
	2025	2024
Fair value	<u>\$ 356,654</u>	<u>\$ 347,160</u>

The investment property - land listed above includes a piece of agricultural land in the amount of NT\$5,600 thousand, which has been acquired due to a settlement of doubtful accounts by the Company but registered under the name of the Company's chairman, Mr. Tseng. The Company has obtained a guarantee note amounting to NT\$5,600 thousand from Mr. Tseng for security purpose.

Investment properties were not pledged.

15. INTANGIBLE ASSETS

	Computer Software	Trademarks	Total
<u>Cost</u>			
Balance at January 1, 2025	\$ 136,890	\$ 16,070	\$ 152,960
Additions	17,989	-	17,989
Disposals	-	-	-
Reclassifications	<u>10,656</u>	<u>-</u>	<u>10,656</u>
Balance at December 31, 2025	<u>\$ 165,535</u>	<u>\$ 16,070</u>	<u>\$ 181,605</u>

(Continued)

	Computer Software	Trademarks	Total
<u>Accumulated amortization</u>			
Balance at January 1, 2025	\$ 66,336	\$ 16,070	\$ 82,406
Amortization expenses	28,726	-	28,726
Disposals	<u>-</u>	<u>-</u>	<u>-</u>
Balance at December 31, 2025	<u>\$ 95,062</u>	<u>\$ 16,070</u>	<u>\$ 111,132</u>
Carrying amount at December 31, 2025	<u>\$ 70,473</u>	<u>\$ -</u>	<u>\$ 70,473</u>
<u>Cost</u>			
Balance at January 1, 2024	\$ 108,060	\$ 16,070	\$ 124,130
Additions	19,945	-	19,945
Disposals	(255)	-	(255)
Reclassifications	<u>9,140</u>	<u>-</u>	<u>9,140</u>
Balance at December 31, 2024	<u>\$ 136,890</u>	<u>\$ 16,070</u>	<u>\$ 152,960</u>
<u>Accumulated amortization</u>			
Balance at January 1, 2024	\$ 43,717	\$ 15,884	\$ 59,601
Amortization expenses	22,874	186	23,060
Disposals	<u>(255)</u>	<u>-</u>	<u>(255)</u>
Balance at December 31, 2024	<u>\$ 66,336</u>	<u>\$ 16,070</u>	<u>\$ 82,406</u>
Carrying amount at December 31, 2024	<u>\$ 70,554</u>	<u>\$ -</u>	<u>\$ 70,554</u> (Concluded)

Except for the aforementioned addition, disposals and recognized amortization, the Company did not have disposal or impairment of other intangible assets during the years ended December 31, 2025 and 2024. Intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:

Computer software	3-10 years
Trademarks	4 years

	For the Year Ended December 31	
	2025	2024
<u>An analysis of depreciation by function</u>		
Operating costs	\$ 1,647	\$ 897
Selling and marketing expenses	4,262	3,044
General and administrative expenses	21,554	18,484
Research and development expenses	<u>1,263</u>	<u>635</u>
	<u>\$ 28,726</u>	<u>\$ 23,060</u>

16. OTHER ASSETS

	<u>December 31</u>	
	<u>2025</u>	<u>2024</u>
<u>Current assets</u>		
Prepayments for purchases	\$ 12,643	\$ 6,001
Other prepaid expense	9,639	8,172
Other current assets	<u>2,272</u>	<u>602</u>
	<u>\$ 24,554</u>	<u>\$ 14,775</u>
<u>Non-current assets</u>		
Prepayments for equipment	\$ 40,195	\$ 32,760
Net defined benefit assets	35,013	30,219
Refundable deposits	4,030	3,625
Other	<u>170</u>	<u>150</u>
	<u>\$ 79,408</u>	<u>\$ 66,754</u>

17. OTHER LIABILITIES

	<u>December 31</u>	
	<u>2025</u>	<u>2024</u>
<u>Current</u>		
Other payables		
Dividends payable	\$ 325,902	\$ 399,971
Payables for purchases of equipment	176,054	43,670
Bonus to employees	116,070	135,836
Salaries and incentive bonus	89,520	100,014
Bonus to directors	27,770	33,196
Accrued VAT payable	1,876	11,708
Other accrued expenses	102,781	135,902
Others	<u>2,042</u>	<u>2,097</u>
	<u>\$ 842,015</u>	<u>\$ 862,394</u>
Other liabilities		
Rent collection in advance	\$ 11	\$ -
Other current liabilities	<u>29,819</u>	<u>20,599</u>
	<u>\$ 29,830</u>	<u>\$ 20,599</u>
<u>Non-current</u>		
Guarantee deposits received	<u>\$ 2,812</u>	<u>\$ 3,124</u>

18. RETIREMENT BENEFIT PLANS

a. Defined contribution plan

The Company adopted a pension plan under the Labor Pension Act (LPA), which is a state-managed defined contribution plan. Under the LPA, the Company makes monthly contributions to employees' individual pension accounts at 6% of monthly salaries and wages.

Expenses under the defined contribution plan for the years ended December 31, 2025 and 2024 were NT\$16,007 thousand and NT\$15,803 thousand, respectively.

b. Defined benefit plans

The defined benefit plans adopted by the Company in accordance with the Labor Standards Act are operated by the government of the ROC. Pension benefits are calculated on the basis of the length of service and average monthly salaries of the 6 months before retirement. The Company contribute amounts equal to 2% of total monthly salaries and wages to a pension fund administered by the pension fund monitoring committee. Pension contributions are deposited in the Bank of Taiwan in the committee's name. Before the end of each year, the Company assesses the balance in the pension fund. If the amount of the balance in the pension fund is inadequate to pay retirement benefits for employees who conform to retirement requirements in the next year, the Company is required to fund the difference in one appropriation that should be made before the end of March of the next year. The pension fund is managed by the Bureau of Labor Funds, Ministry of Labor (the "Bureau"); the Company has no right to influence the investment policy and strategy.

The amounts included in the parent company only balance sheets in respect of the Company's defined benefit plans are as follows:

	December 31	
	2025	2024
Present value of defined benefit obligation	\$ 8,180	\$ 8,923
Fair value of plan assets	<u>(43,193)</u>	<u>(39,142)</u>
Net defined benefit liabilities (assets)	<u>\$ (35,013)</u>	<u>\$ (30,219)</u>

Movements in net defined benefit liabilities (assets) were as follows:

	Present Value of the Defined Benefit Obligation	Fair Value of the Plan Assets	Net Defined Benefit Liabilities (Assets)
Balance at January 1, 2025	\$ 8,923	\$ (39,142)	\$ (30,219)
Service cost			
Past service cost	849	-	849
Net interest expense (income)	<u>146</u>	<u>(660)</u>	<u>(514)</u>
Recognized in profit or loss	<u>995</u>	<u>(660)</u>	<u>335</u>
Remeasurement			
Return on plan assets (excluding amounts included in net interest)	-	(2,618)	(2,618)

(Continued)

	Present Value of the Defined Benefit Obligation	Fair Value of the Plan Assets	Net Defined Benefit Liabilities (Assets)
Actuarial (gain) loss			
Changes in financial assumptions	\$ 230	\$ -	\$ 230
Experience adjustments	<u>(57)</u>	<u>-</u>	<u>(57)</u>
Recognized in other comprehensive income	<u>173</u>	<u>(2,618)</u>	<u>(2,445)</u>
Contributions from the employer	<u>-</u>	<u>(1,835)</u>	<u>(1,835)</u>
Benefit payments	<u>(1,062)</u>	<u>1,062</u>	<u>-</u>
Curtailment	<u>(849)</u>	<u>-</u>	<u>(849)</u>
Balance at December 31, 2025	<u>\$ 8,180</u>	<u>\$ (43,193)</u>	<u>\$ (35,013)</u>
Balance at January 1, 2024	<u>\$ 11,344</u>	<u>\$ (33,944)</u>	<u>\$ (22,600)</u>
Service cost			
Past service cost	221	-	221
Net interest expense (income)	<u>141</u>	<u>(438)</u>	<u>(297)</u>
Recognized in profit or loss	<u>362</u>	<u>(438)</u>	<u>(76)</u>
Remeasurement			
Return on plan assets (excluding amounts included in net interest)	-	(2,957)	(2,957)
Actuarial gain			
Changes in financial assumptions	(418)	-	(418)
Experience adjustments	<u>(1,376)</u>	<u>-</u>	<u>(1,376)</u>
Recognized in other comprehensive income	<u>(1,794)</u>	<u>(2,957)</u>	<u>(4,751)</u>
Contributions from the employer	<u>-</u>	<u>(2,101)</u>	<u>(2,101)</u>
Benefit payments	<u>(769)</u>	<u>298</u>	<u>(471)</u>
Curtailment	<u>(220)</u>	<u>-</u>	<u>(220)</u>
Balance at December 31, 2024	<u>\$ 8,923</u>	<u>\$ (39,142)</u>	<u>\$ (30,219)</u> (Concluded)

Through the defined benefit plans under the Labor Standards Act, the Company is exposed to the following risks:

- 1) Investment risk: The plan assets are invested in domestic and foreign equity and debt securities, bank deposits, etc. The investment is conducted at the discretion of the Bureau or under the mandated management. However, in accordance with relevant regulations, the return generated by plan assets shall not be below the interest rate for a 2-year time deposit with local banks.
- 2) Interest risk: A decrease in the government bond interest rate will increase the present value of the defined benefit obligation; however, this will be partially offset by an increase in the return on the plans' debt investments.
- 3) Salary risk: The present value of the defined benefit obligation is calculated using the future salaries of plan participants. As such, an increase in the salaries of the plan participants will increase the present value of the defined benefit obligation.

The actuarial valuations of the present value of the defined benefit obligation were carried out by qualified actuaries. The significant assumptions used for the purposes of the actuarial valuations are as follows:

	<u>December 31</u>	
	2025	2024
Discount rate	1.40%	1.65%
Expected rate of salary increase	3.00%	3.00%

If possible reasonable changes in each of the significant actuarial assumptions will occur and all other assumptions will remain constant, the present value of the defined benefit obligation will increase (decrease) as follows:

	<u>December 31</u>	
	2025	2024
Discount rate		
0.25% increase	<u>\$ (230)</u>	<u>\$ (249)</u>
0.25% decrease	<u>\$ 239</u>	<u>\$ 258</u>
Expected rate of salary increase/decrease		
0.25% increase	<u>\$ 234</u>	<u>\$ 254</u>
0.25% decrease	<u>\$ (227)</u>	<u>\$ (246)</u>

The sensitivity analysis presented above may not be representative of the actual changes in the present value of the defined benefit obligation as it is unlikely that changes in assumptions will occur in isolation of one another as some of the assumptions may be correlated.

	<u>December 31</u>	
	2025	2024
Expected contributions to the plans for the next year	<u>\$ 1,748</u>	<u>\$ 1,873</u>
Average duration of the defined benefit obligation	11 years	11 years

Employee benefit expenses in respect of the Company's defined benefit retirement plans were calculated using the actuarially determined pension cost discount rate; expenses under the defined benefit plan for the years ended December 31, 2025 and 2024 were NT\$335 thousand and NT\$(76) thousand, respectively.

19. EQUITY

a. Share capital

1) Ordinary shares

	<u>December 31</u>	
	2025	2024
Shares authorized (in thousands of shares)	<u>180,000</u>	<u>180,000</u>
Shares authorized, par value \$10 (in thousands of dollars)	<u>\$ 1,800,000</u>	<u>\$ 1,800,000</u>
Shares issued and fully paid (in thousands of shares)	<u>148,137</u>	<u>148,137</u>
Shares issued through public issue	\$ 1,481,374	\$ 1,481,374
Shares issued through private placement	-	-
Shares issued and fully paid (in thousands of dollars)	<u>\$ 1,481,374</u>	<u>\$ 1,481,374</u>

Each share possesses one voting right and a right to receive dividends.

On January 14, 2021, the Company held the first extraordinary shareholders' meeting and a resolution was passed to increase cash capital by issuing ordinary shares through private placement with Uni-President Enterprise Co., Ltd., a strategic investor, as the subscriber. The purpose of the capital increase is to raise funds for capital expenditures, to enrich working capital and help strengthen the capital structure. On January 14, 2021, the Company's s resolved to offer for subscription and issued 11,851 thousand ordinary shares of the Company. The subscription price was \$170 per share, and a total of \$2,014,670 thousand in cash was received. The record date of cash capital increase was January 19, 2021. The rights and obligations of the shareholders of the ordinary shares issued through this private placement are the same as those of the shareholders of the Company's issued ordinary shares. However, in accordance with Article 43-8 of the Securities and Exchange Act, the ordinary shares of this private placement shall not be freely transferred within three years from the date of subscription. The Company's Board of Directors, on May 13, 2024, resolved to publicly issue the privately placed common shares and applied with the Taiwan Stock Exchange for the shares to take effect on August 14, 2024.

b. Capital surplus

	<u>December 31</u>	
	<u>2025</u>	<u>2024</u>
May be used to offset a deficit, distributed as cash dividends, or transferred to share capital (1)		
Additional paid-in capital	\$ 2,850,440	\$ 2,850,440
Treasury share transactions	2,672	2,672
<u>May only be used to offset a deficit</u>		
Convertible bonds - expired share option	150	150
Treasury share transactions - share option	6,749	6,749
Arising from share of changes in capital surplus of associates	2,809	2,809
Recognition of Changes in Ownership Interests in Subsidiaries(2)	721	-
Others (3)	<u>17,963</u>	<u>15,777</u>
	<u>\$ 2,881,504</u>	<u>\$ 2,878,597</u>

- 1) Such capital surplus may be used to offset a deficit; in addition, when the Company has no deficit, such capital surplus may be distributed as cash dividends or transferred to share capital (limited to a certain percentage of the Company's capital surplus and to once a year).
- 2) Such capital surplus arises from the effect of changes in ownership interest in subsidiary resulted from equity transactions other than actual disposal or acquisition.
- 3) Others are unclaimed dividends.

c. Retained earnings and dividends policy

The shareholders of the Company held their regular shareholders' meeting on May 30, 2024, and in that meeting, resolved the amendments to the Company's Articles of Incorporation (the "Articles"). The Company's earnings distribution or loss off-setting proposal may be proposed at the close of each half a year.

Under the dividends policy as set forth in the amended Articles, the Company's earnings distribution or loss off-setting proposal may be proposed at the close of each half a year. Where the Company has a profit at the end of each half a year, the Company shall estimate and reserve the taxes to be paid, offset losses according to regulation, estimate employees and directors' compensation, and allocate 10% as legal reserve, unless accumulated legal reserve has reached the total paid-in capital. Then, set aside or reverse a special reserve in accordance with relevant regulations. If a surplus remains, the balance combined with undistributed retained earnings from preceding periods shall be distributed according to the distribution plan proposed by the Board of Directors. If distributing in the form of cash, it shall be approved by the Board of Directors. If distributing in the form of new shares to be issue, the plan shall be submitted to the shareholders' meeting for approval.

The Company shall pay taxes and cover accumulated deficits and then make appropriate provisions of about 10% for legal reserve. In the case of making profit earnings at the close of business year after settlement, while the legal reserve reaches the paid-in capital of the Company, it may not make an provision anymore. The Company may make appropriate provision or reverse to special reserve for the surplus. In the event of an undistributed earnings of current year, it shall combine with accumulated undistributed earnings to apply for formulating earning distribution proposal to Board of Directors. Distribution in cash shall be determined after a resolution adopted by a majority vote at a meeting of the Board of Directors attended by two-thirds of the total number of directors; and in addition thereto a report of such distribution shall be submitted to the shareholders' meeting. Distribution in new share issuance shall be determined after a resolution at the shareholders' meeting.

According to the Company's Articles of Association before amendment, the Company shall distribute its annual earnings, if any, in the sequence listed below.

- 1) Paying taxes;
- 2) Offsetting losses of previous years;
- 3) Setting aside as legal reserve 10% of the remaining profit;
- 4) Setting aside or reversing a special reserve in accordance with the laws and regulations; and
- 5) Any remaining profit together with any undistributed retained earnings shall be used by the Company's Board of Directors as the basis for proposing a distribution plan, which should be resolved in the shareholders' meeting for the distribution of dividends and bonuses to shareholders.

For the policies on the distribution of compensation of employees and remuneration of directors after the amendment, refer to compensation of employees and remuneration of directors in Note 21-g.

The Company's dividend policy shall be determined pursuant to the factors, such as the investment environment, capital requirement, domestic and overseas competition environment, current and future business development plan, as well as shareholders' interests. The distribution of shareholders dividend shall not be lower than 60% of the unappropriated earnings of the current year. However, the shareholders may resolve not to distribute dividends if the accumulated earnings were lower than 10% of the paid-in capital. Dividends can be distributed in the form of cash or shares or a combination of both cash and stock, out of which at least 10% of the total dividends distributed shall be in cash.

Appropriation of earnings to the legal reserve shall be made until the legal reserve equals the Company's paid-in capital. The legal reserve may be used to offset deficits. If the Company has no deficit and the legal reserve has exceeded 25% of the Company's paid-in capital, the excess may be transferred to capital or distributed in cash.

The appropriations of earnings for the second half of 2024 and the first half of 2024 that were approved by the Board of Directors on February 26, 2025 and November 11, 2024, respectively, were as follows:

	Second Half of 2024	First Half of 2024
Legal reserve	<u>\$ 86,683</u>	<u>\$ 58,564</u>
Special reserve	<u>\$ (12,782)</u>	<u>\$ (32,014)</u>
Cash dividends	<u>\$ 622,177</u>	<u>\$ 399,971</u>
Cash dividends per share (NT\$)	<u>\$ 4.2</u>	<u>\$ 2.7</u>

The appropriation of cash dividends for the second half of 2024 was approved by the Board of Directors on February 26, 2025. The other appropriations of earnings for 2024 was approved in the shareholders' meeting on May 26, 2025.

The appropriations of earnings for 2023 that was proposed in the shareholders' meeting on May 30, 2024, was as follows:

	December 31, 2023
Legal reserve	<u>\$ 145,293</u>
Special reserve	<u>\$ 8,729</u>
Cash dividends	<u>\$ 1,022,148</u>
Cash dividends per share (NT\$)	<u>\$ 6.9</u>

The appropriations of earnings for the second half of 2025 and the first half of 2025 that were approved by the Board of Directors on March 4, 2026 and November 12, 2025, respectively, were as follows:

	Second Half of 2025	First Half of 2025
Legal reserve	<u>\$ 74,309</u>	<u>\$ 47,738</u>
Special reserve	<u>\$ (118,823)</u>	<u>\$ 107,997</u>
Cash dividends	<u>\$ 562,922</u>	<u>\$ 325,902</u>
Cash dividends per share (NT\$)	<u>\$ 3.8</u>	<u>\$ 2.2</u>

The other appropriations of earnings for 2025 will be approved in the shareholders' meeting on May 26, 2026 (expected).

d. Other equity items

1) Exchange differences on translating the financial statements of foreign operations

	For the Year Ended December 31	
	2025	2024
Balance at beginning of year	\$ (34,761)	\$ (79,665)
Recognized for the year		
Exchange differences on translating the financial statements of foreign operations	<u>10,825</u>	<u>44,904</u>
Balance at end of year	<u>\$ (23,936)</u>	<u>\$ (34,761)</u>

2) Unrealized gain (loss) on financial assets at FVTOCI

	For the Year Ended December 31	
	2025	2024
Balance at beginning of year	\$ -	\$ (108)
Recognized for the year		
Unrealized gain - equity instruments	-	(98)
Other comprehensive loss for the period	-	(98)
Transfer of accumulated gain or loss on disposal of equity instruments to retained earnings	-	(10)
Balance at end of year	<u>\$ -</u>	<u>\$ -</u>

20. REVENUE

	For the Year Ended December 31	
	2025	2024
Revenue from contracts with customers		
Revenue from the sale of goods	\$ 2,132,824	\$ 2,353,773
Revenue from the rendering of services	<u>720,485</u>	<u>474,085</u>
	<u>\$ 2,853,309</u>	<u>\$ 2,827,858</u>

a. Disaggregation of revenue

1) Type of goods or services and timing of revenue recognition:

For the year ended December 31, 2025

	Reportable Segments			Total
	MLM	Distribution	ODM/OEM	
<u>Type of goods or services</u>				
Sale of goods	\$ 1,567,673	\$ 565,151	\$ -	\$ 2,132,824
Rendering of services	<u>-</u>	<u>-</u>	<u>720,485</u>	<u>720,485</u>
	<u>\$ 1,567,673</u>	<u>\$ 565,151</u>	<u>\$ 720,485</u>	<u>\$ 2,853,309</u>

Timing of revenue recognition

Satisfied at a point in time	<u>\$ 1,567,673</u>	<u>\$ 565,151</u>	<u>\$ 720,485</u>	<u>\$ 2,853,309</u>
------------------------------	---------------------	-------------------	-------------------	---------------------

For the year ended December 31, 2024

	Reportable Segments			Total
	MLM	Distribution	ODM/OEM	
<u>Type of goods or services</u>				
Sale of goods	\$ 1,736,294	\$ 617,479	\$ -	\$ 2,353,773
Rendering of services	<u>-</u>	<u>-</u>	<u>474,085</u>	<u>474,085</u>
	<u>\$ 1,736,294</u>	<u>\$ 617,479</u>	<u>\$ 474,085</u>	<u>\$ 2,827,858</u>

Timing of revenue recognition

Satisfied at a point in time	<u>\$ 1,736,294</u>	<u>\$ 617,479</u>	<u>\$ 474,085</u>	<u>\$ 2,827,858</u>
------------------------------	---------------------	-------------------	-------------------	---------------------

2) Type of goods

<u>Type of goods</u>	<u>For the Year Ended December 31</u>	
	2025	2024
Health food	\$ 1,871,706	\$ 2,100,312
ODM/OEM	720,485	474,085
Beverage	209,413	225,668
Cosmetics	46,849	24,195
Others (Note)	<u>4,856</u>	<u>3,598</u>
	<u>\$ 2,853,309</u>	<u>\$ 2,827,858</u>

Note: Others include general food and pet food.

b. Contract balances

	December 31, 2025	December 31, 2024	January 1, 2024
Notes and accounts receivable, net	<u>\$ 140,995</u>	<u>\$ 90,455</u>	<u>\$ 61,161</u>
Accounts receivable from related parties	<u>\$ 207,385</u>	<u>\$ 294,841</u>	<u>\$ 368,421</u>
Contract liabilities - current			
Rendering of services	<u>\$ 38,918</u>	<u>\$ 32,908</u>	<u>\$ 23,924</u>

The changes in the balance of contract liabilities primarily resulted from the timing difference between the Company's satisfaction of performance obligations and the respective customer's payment.

Revenue in the current year that was recognized from the contract liability balance at the beginning of the year was summarized as follows:

	<u>For the Year Ended December 31</u>	
	2025	2024
From contract liabilities at the start of the year		
Revenue from the rendering of services	<u>\$ 32,512</u>	<u>\$ 28,163</u>

21. NET PROFIT (LOSS) FROM CONTINUING OPERATIONS

a. Interest income

	<u>For the Year Ended December 31</u>	
	2025	2024
Financial assets at amortized cost	<u>\$ 8,580</u>	<u>\$ 10,548</u>

b. Other income

	For the Year Ended December 31	
	2025	2024
Board compensation income	\$ 73,909	\$ 82,970
Rental income	3,266	3,265
Others (Note 24)	<u>7,544</u>	<u>15,039</u>
	<u>\$ 84,719</u>	<u>\$ 101,274</u>

c. Other gains and losses

	For the Year Ended December 31	
	2025	2024
Fair value changes of financial assets and financial liabilities		
Financial assets mandatorily classified as at FVTPL	\$ -	\$ 192
Net foreign exchange gain	848	3,233
Gains on modification of lease agreements	-	1,179
Gains on disposal of property, plant and equipment	160	30
Gain on Disposal of Investments Accounted for Using the Equity Method	315	-
Others	<u>(267)</u>	<u>(531)</u>
	<u>\$ 1,056</u>	<u>\$ 4,103</u>

d. Finance costs

	For the Year Ended December 31	
	2025	2024
Interest on lease liabilities	\$ 2,052	\$ 2,022
Imputed interest on deposit	<u>78</u>	<u>16</u>
	<u>\$ 2,130</u>	<u>\$ 2,038</u>

e. Depreciation and amortization

	For the Year Ended December 31	
	2025	2024
An analysis of depreciation by function		
Operating costs	\$ 273,616	\$ 240,703
Operating expenses (Note 1)	<u>88,588</u>	<u>91,114</u>
	<u>\$ 362,204</u>	<u>\$ 331,817</u>
An analysis of amortization by function		
Operating costs	\$ 1,647	\$ 897
Operating expenses	<u>27,079</u>	<u>22,163</u>
	<u>\$ 28,276</u>	<u>\$ 23,060</u>

Note 1: The aforementioned depreciation included the depreciation of investment properties, which amounted to NT\$267 thousand and NT\$266 thousand for the years ended December 31, 2025 and 2024, respectively, and was recognized by the Company in other gains and losses.

Note 2: Refer to Note 15 for information relating to the line item in which any amortization of intangible assets is included.

f. Employee benefits expense

	<u>For the Year Ended December 31</u>	
	2025	2024
Short-term benefits	<u>\$ 566,855</u>	<u>\$ 588,167</u>
Post-employment benefits (Note 18)		
Defined contribution plan	16,007	15,803
Defined benefit plans	<u>335</u>	<u>(76)</u>
	<u>16,342</u>	<u>15,727</u>
Other employee benefits	<u>20,090</u>	<u>20,110</u>
 Total employee benefits expense	 <u>\$ 603,287</u>	 <u>\$ 624,004</u>
 An analysis of employee benefits expense by function		
Operating costs	\$ 235,844	\$ 218,571
Operating expenses	<u>367,443</u>	<u>405,433</u>
	<u>\$ 603,287</u>	<u>\$ 624,004</u>

g. Compensation of employees and remuneration of directors

According to the Company's Articles of Incorporation, 6%-8% of profit of the current year is distributable as compensation of employees and no higher than 2% of profit of the current year is distributable as remuneration of directors. However, the Company has to first offset accumulated losses, if any. In accordance with the amendments to the Securities and Exchange Act in August 2024, the Company resolved the amendments to the Company's Articles at their 2025 shareholders' meeting. The amendments explicitly stipulate that no less than 30% of the compensation of employees in the current year shall be distributed to non-executive employees. For the years ended December 31, 2025 and 2024, the compensation of employees (including non-executive employees) and the remuneration of directors are as follows:

Accrual rate

	<u>For the Year Ended December 31</u>	
	2025	2024
Compensation of employees	8%	8%
Remuneration of directors	2%	2%

Amount

	<u>For the Year Ended December 31</u>	
	2025	2024
Compensation of employees	\$ 111,082	\$ 132,782
Remuneration of directors	27,770	33,196

If there is a change in the amounts after the annual parent company only financial statements are authorized for issue, the differences are recorded as a change in the accounting estimate.

The appropriations of earnings for the compensation of employees and remuneration of directors for 2025 and 2024 that were resolved by the Company's Board of Directors on March 4, 2026 and February 26, 2025, respectively, are as shown below:

	For the Year Ended December 31	
	2025	2024
	Cash	Cash
Compensation of employees	\$ 111,082	\$ 132,782
Remuneration of directors	27,770	33,196

There is no difference between the actual amounts of compensation of employees and remuneration of directors paid and the amounts recognized in the parent company only financial statements for the years ended December 31, 2024 and 2023.

Information on the compensation of employees and remuneration of directors resolved by the Company's Board of Directors is available at the Market Observation Post System website of the Taiwan Stock Exchange.

22. INCOME TAXES

a. Income tax recognized in profit or loss

Major components of income tax expense are as follows:

	For the Year Ended December 31	
	2025	2024
Current tax		
In respect of the current year	\$ 55,641	\$ 69,554
Income tax on unappropriated earnings	16,494	13,838
Adjustments for prior years	<u>(46,558)</u>	<u>(42,764)</u>
	25,577	40,628
Deferred tax		
In respect of the current year	<u>5,788</u>	<u>4,873</u>
Income tax expense recognized in profit or loss	<u>\$ 31,365</u>	<u>\$ 45,501</u>

A reconciliation of accounting profit and income tax expense is as follows:

	For the Year Ended December 31	
	2025	2024
Profit before tax from continuing operations	<u>\$ 1,249,670</u>	<u>\$ 1,493,800</u>
Income tax expense calculated at the statutory rate	\$ 249,934	\$ 298,760
Income tax on unappropriated earnings	16,494	13,838
Others	(188,505)	(224,333)
Adjustments for prior years' tax	<u>(46,558)</u>	<u>(42,764)</u>
Income tax expense recognized in profit or loss	<u>\$ 31,365</u>	<u>\$ 45,501</u>

b. Income tax recognized in other comprehensive income

	<u>For the Year Ended December 31</u>	
	2025	2024
<u>Deferred tax</u>		
In respect of the current year		
Remeasurement of defined benefit plans for subsidiaries recognized using the equity method	\$ 54	\$ 91
Remeasurement of defined benefit plans	<u>489</u>	<u>950</u>
Total income tax recognized in other comprehensive income	<u>\$ 543</u>	<u>\$ 1,041</u>

c. Deferred tax assets and liabilities

The movements of deferred tax assets and deferred tax liabilities are as follows:

For the year ended December 31, 2025

Deferred Tax Assets	Opening Balance	Recognized in Profit or Loss	Recognized in Other Comprehensive Income	Closing Balance
Temporary differences				
Employee benefits payable	\$ <u>284</u>	\$ <u>-</u>	\$ <u>-</u>	\$ <u>284</u>

Deferred Tax Liabilities	Opening Balance	Recognized in Profit or Loss	Recognized in Other Comprehensive Income	Closing Balance
Temporary differences				
Unrealized revaluation	\$ (68,463)	\$ -	\$ -	\$ (68,463)
Defined benefit liabilities (assets) - non-current	(1,919)	-	(489)	(2,408)
Investment loss under equity method	<u>(11,871)</u>	<u>(5,788)</u>	<u>-</u>	<u>(17,659)</u>
	<u>\$ (82,253)</u>	<u>\$ (5,788)</u>	<u>\$ (489)</u>	<u>\$ (88,503)</u>

For the year ended December 31, 2024

Deferred Tax Assets	Opening Balance	Recognized in Profit or Loss	Recognized in Other Comprehensive Income	Closing Balance
Temporary differences				
Employee benefits payable	\$ 284	\$ -	\$ -	\$ 284
Allowance for inventory loss	<u>893</u>	<u>(893)</u>	<u>-</u>	<u>-</u>
	<u>\$ 1,177</u>	<u>\$ (893)</u>	<u>\$ -</u>	<u>\$ 284</u>

Deferred Tax Liabilities	Opening Balance	Recognized in Profit or Loss	Recognized in Other Comprehensive Income	Closing Balance
Temporary differences				
Unrealized revaluation	\$ (68,463)	\$ -	\$ -	\$ (68,463)
Defined benefit liabilities (assets) - non-current	(969)	-	(950)	(1,919)
Investment loss under equity method	<u>(7,891)</u>	<u>(3,980)</u>	<u>-</u>	<u>(11,871)</u>
	<u>\$ (77,323)</u>	<u>\$ (3,980)</u>	<u>\$ (950)</u>	<u>\$ (82,253)</u>

d. Income tax assessments

The tax authorities have assessed the income tax returns of the Company through 2023.

23. EARNINGS PER SHARE

Unit: NT\$ Per Share

	<u>For the Year Ended December 31</u>	
	2025	2024
Basic earnings per share	<u>\$ 8.22</u>	<u>\$ 9.78</u>
Diluted earnings per share	<u>\$ 8.17</u>	<u>\$ 9.71</u>

The earnings and weighted average number of ordinary shares outstanding used in the computation of earnings per share are as follows:

Net profit for the year

	<u>For the Year Ended December 31</u>	
	2025	2024
Earnings used in the computation of basic and diluted earnings per share	<u>\$ 1,218,305</u>	<u>\$ 1,448,299</u>

Weighted average number of ordinary shares outstanding

Unit: In Thousands of Shares

	<u>For the Year Ended December 31</u>	
	2025	2024
Weighted average number of ordinary shares used in the computation of basic earnings per share	148,137	148,137
Effect of potentially dilutive ordinary shares		
Compensation of employees	<u>1,016</u>	<u>1,025</u>
Weighted average number of ordinary shares used in the computation of diluted earnings per share	<u>149,153</u>	<u>149,162</u>

If the Company offered to settle the compensation or bonuses paid to employees in cash or shares, the Company assumed that the entire amount of the compensation or bonuses will be settled in shares, and the resulting potential shares were included in the weighted average number of shares outstanding used in the computation of diluted earnings per share, as the effect is dilutive. Such dilutive effect of the potential shares is included in the computation of diluted earnings per share until the number of shares to be distributed to employees is resolved in the following year.

24. GOVERNMENT GRANTS

The Company applied for the subsidy program “Large-to-Small Low Carbon and Intelligent Manufacturing Upgrade and Transformation”, proposed by the Ministry of Economic Affairs. The subsidies approved amounted to NT\$18,000 thousand. As of December 31, 2025, a total of NT\$3,348 thousand has been recognized as subsidy income, which was recorded in other income. The Company provided a performance letter of guarantee as collateral, which amounted to NT\$18,000 thousand.

25. CASH FLOW INFORMATION

a. Non-cash transactions

The Company entered into the following non-cash investing and financing activities which were not reflected in the financial statements of cash flows for the years ended December 31, 2025 and 2024:

	<u>For the Year Ended December 31</u>	
	2025	2024
Additions of property, plant and equipment	\$(477,322)	\$ (482,140)
Changes in prepayments for purchases	(47,657)	(67,520)
Changes in payables for purchases of equipment	<u>132,263</u>	<u>(35,649)</u>
Payments for acquisition of property, plant and equipment	<u>\$ (392,716)</u>	<u>\$ (585,309)</u>

b. Changes in liabilities arising from financing activities

For the year ended December 31, 2025

	January 1, 2025	Cash Flows	<u>Non-cash Changes</u>		December 31, 2025
			Lease Change	Finance Costs	
Guarantee deposits received	\$ 3,124	\$ (312)	\$ -	\$ -	\$ 2,812
Lease liabilities	<u>107,525</u>	<u>(24,271)</u>	<u>16,397</u>	<u>2,052</u>	<u>101,703</u>
	<u>\$ 110,649</u>	<u>\$ (24,583)</u>	<u>\$ 16,397</u>	<u>\$ 2,052</u>	<u>\$ 104,515</u>

For the year ended December 31, 2024

	January 1, 2024	Cash Flows	<u>Non-cash Changes</u>		December 31, 2024
			Lease Change	Finance Costs	
Guarantee deposits received	\$ 3,717	\$ (593)	\$ -	\$ -	\$ 3,124
Lease liabilities	<u>125,576</u>	<u>(22,626)</u>	<u>2,553</u>	<u>2,022</u>	<u>107,525</u>
	<u>\$ 129,293</u>	<u>\$ (23,219)</u>	<u>\$ 2,553</u>	<u>\$ 2,022</u>	<u>\$ 110,649</u>

26. CAPITAL MANAGEMENT

The objective of the Company's capital management is maintaining a good capital structure and to ensure the ability to operate continuously, in order to provide returns to stockholders. The Company's capital structure management strategies were based on the industry size of the Company, industry's future growth, product roadmaps, and changes in the external environment and other factors. The Company plans the required capacity and the necessary plant and equipment to achieve this capacity and the corresponding capital expenditure according to those strategies. The Company then calculates the required working capital and cash based on industry characteristics, and estimates the possible product margins, operating margin and cash flow. In order to determine the most appropriate capital structure, the Company takes into consideration cyclical fluctuations in industrial, product life cycle and other risk factors.

27. FINANCIAL INSTRUMENTS

- a. Fair value of financial instruments not measured at fair value

The Company's management considers the book value of financial instruments that are not measured at fair value in the financial statements approximate the fair value.

- b. Fair value of financial instruments measured at fair value on a recurring basis

Reconciliation of Level 3 fair value measurements of financial instruments

For the year ended December 31, 2024

Financial Assets	Financial Assets at FVTOCI Equity Instruments
Balance at beginning of year	\$ 128
Recognized in other comprehensive income (included in unrealized gain (loss) on financial assets at FVTOCI)	(98)
Disposals	<u>(30)</u>
Balance at end of year	<u>\$ -</u>

- c. Categories of financial instruments

	December 31	
	2025	2024
<u>Financial assets</u>		
Financial assets at amortized cost		
Cash and cash equivalents	\$ 1,069,339	\$ 886,509
Financial assets at amortized cost	10,800	9,600
Notes and accounts receivable, net	140,995	90,455
Accounts receivable from related parties	207,385	294,841
Other receivables	13,784	6,939
Other receivables from related parties	<u>74,040</u>	<u>83,879</u>
	<u>\$ 1,516,343</u>	<u>\$ 1,372,223</u>

(Continued)

	<u>December 31</u>	
	<u>2025</u>	<u>2024</u>
<u>Financial liabilities</u>		
Financial liabilities at amortized cost		
Notes and accounts payable	\$ 320,739	\$ 265,321
Other payables	842,015	862,394
Other payables to related parties	<u>4,020</u>	<u>1,716</u>
	<u>\$ 1,166,774</u>	<u>\$ 1,129,431</u>
		(Concluded)

d. Financial risk management objectives and policies

The Company's principal financial risk management objective is to manage the market risk, credit risk and liquidity risk related to its operating activities. The Company identifies, measures and manages the aforementioned risks based on the Company's policy and risk appetite.

The Company has established appropriate policies, procedures and internal controls for financial risk management. Before entering into significant transactions, approval process by the Board of Directors must be carried out based on related protocols and internal control procedures. The Company complies with its financial risk management policies.

1) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise currency risk (see (a) below) and interest rate risk (see (b) below).

In practice, it is rarely the case that a single risk variable will change independently from other risk variables. There are usually interdependencies between risk variables. However, the sensitivity analysis disclosed below does not take into account the interdependencies between risk variables.

There has been no change to the Company's exposure to market risks or the manner in which these risks are managed and measured.

a) Foreign currency risk

The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's operating activities (when revenue or expense is denominated in a different currency from the Company's functional currency) and the Company's net investments in foreign subsidiaries. The purpose of the Company's management of the exchange rate risk is for the purpose of hedging and not for profit.

The Company has certain foreign currency receivables to be denominated in the same foreign currency as certain foreign currency payables, therefore natural hedging is applied. Furthermore, as net investments in foreign subsidiaries are for strategic purposes, they are not hedged by the Company.

The carrying amounts of the Company's foreign currency denominated monetary assets and monetary liabilities are set out in Note 31.

Sensitivity analysis

The Company is mainly exposed to the USD.

The following table details the Company's sensitivity to a 10% change in the functional currency against the relevant foreign currencies. The sensitivity analysis included only outstanding foreign currency denominated monetary items, and adjusts their translation at the end of the reporting period for a 10% change in foreign currency rates. A positive number below indicates a change in pre-tax profit associated with the functional currency strengthening 10% against the relevant currency.

	Currency USD Impact	
	For the Year Ended December 31	
	2025	2024
Profit or loss	\$ 11,940	\$ 7,284

b) Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk because entities in the Company borrow funds at both fixed and floating interest rates. The Company is also exposed to interest rate risk related to its investments in floating rate debt instruments. The risk is managed by the Company by maintaining an appropriate mix of fixed and floating rate borrowings.

The carrying amounts of the Company's financial assets and financial liabilities with exposure to interest rates at the end of the reporting period were as follows:

	December 31	
	2025	2024
Fair value interest rate risk		
Financial assets	\$ 45,373	\$ 29,271
Financial liabilities	101,703	107,525
Cash flow interest rate risk		
Financial assets	1,034,524	866,547

Sensitivity analysis

The sensitivity analysis below was determined based on the Company's exposure to interest rates for non-derivative instruments at the end of the reporting period. For floating rate liabilities, the analysis was prepared assuming the amount of each liability outstanding at the end of the reporting period was outstanding for the whole year.

If interest rates had been changed by 10 basis points and all other variables were held constant, the Company's pre-tax profit for the years ended December 31, 2025 and 2024 would have changed by NT\$1,035 thousand and NT\$867 thousand, respectively, which was mainly due to fluctuations in the net asset's variable interest rate.

2) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Company. As at the end of the reporting period, the Company's maximum exposure to credit risk, which would cause a financial loss to the Company due to the failure of the

counterparty to discharge its obligation, could be equal to the total of the carrying amount of the respective recognized financial assets as stated in the balance sheets.

Customer credit risk is managed by each business unit subject to the Company's established policy, procedures and control relating to customer credit risk management. Credit limits are established for all customers based on their financial position, rating from credit rating agencies, historical experience, prevailing economic condition and the Company's internal rating criteria etc. The Company also uses certain credit enhancement instruments such as contractual liabilities at appropriate times to reduce the credit risk of specific customers.

The Company transacts with a large number of unrelated customers and thus, credit risk is not highly concentrated.

Credit risk from balances with banks, fixed income securities and other financial instruments is managed by the Company's treasury in accordance with the Company's policy. The Company only transacts with counterparties approved by the internal control procedures, which are banks and financial institutions, companies and government entities with good credit rating and with no significant default risk. Consequently, there is no significant credit risk for these counterparties.

3) Liquidity risk

The Company's objective is to finance its operations and mitigate the effects of fluctuations in cash flows through the use of cash and cash equivalents and highly liquid equity investments. In addition, management monitors the utilization of bank borrowings and ensures compliance with loan covenants.

The Company relies on bank borrowings as a significant source of liquidity. As of December 31, 2025 and 2024, the Company had available unutilized short-term bank loan facilities set out in (b) below.

a) Liquidity and interest rate risk tables for non-derivative financial liabilities

The following table details the Company's remaining contractual maturities for its non-derivative financial liabilities with agreed upon repayment periods. The table has been drawn up based on the undiscounted cash flows of financial liabilities from the earliest date on which the Company can be required to pay. The table includes both interest and principal cash flows. Specifically, bank loans with a repayment on demand clause were included in the earliest time band regardless of the probability of the banks choosing to exercise their rights. The maturity dates for other non-derivative financial liabilities were based on the agreed upon repayment dates.

December 31, 2025

	On Demand or Less than 6 Months	6-12 Months	1-2 Years	2-5 Years	5+ Years	Total
Notes and accounts payable	\$ 320,739	\$ -	\$ -	\$ -	\$ -	\$ 320,739
Other payables (related parties included)	707,183	138,852	-	-	-	846,035
Lease liabilities	<u>12,360</u>	<u>12,219</u>	<u>23,920</u>	<u>20,301</u>	<u>45,831</u>	<u>114,631</u>
	<u>\$ 1,040,282</u>	<u>\$ 151,071</u>	<u>\$ 23,920</u>	<u>\$ 20,301</u>	<u>\$ 45,831</u>	<u>\$ 1,281,405</u>

Additional information about the maturity analysis for financial liabilities:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$ 24,579</u>	<u>\$ 44,221</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 12,021</u>

December 31, 2024

	On Demand or Less than 6 Months	6-12 Months	1-2 Years	2-5 Years	5+ Years	Total
Notes and accounts payable	\$ 265,321	\$ -	\$ -	\$ -	\$ -	\$ 265,321
Other payables (related parties included)	698,132	165,978	-	-	-	864,110
Lease liabilities	<u>10,755</u>	<u>10,486</u>	<u>20,756</u>	<u>31,623</u>	<u>48,084</u>	<u>121,704</u>
	<u>\$ 974,208</u>	<u>\$ 176,464</u>	<u>\$ 20,756</u>	<u>\$ 31,623</u>	<u>\$ 48,084</u>	<u>\$ 1,251,135</u>

Additional information about the maturity analysis for financial liabilities:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$ 21,241</u>	<u>\$ 52,379</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 14,274</u>

b) Financing facilities

	<u>December 31</u>	
	2025	2024
Short-term borrowings amount		
Amount unused	<u>\$ 538,000</u>	<u>\$ 738,000</u>

28. TRANSACTIONS WITH RELATED PARTIES

Details of transactions between the Company and related parties are disclosed as follows:

a. Related party name and category

<u>Related Party Name</u>	<u>Related Party Category</u>	<u>Relationship with the Company</u>
Sheng-Lin Tseng	Substantive related party	Chairman of the Company
Pro-partner Ltd. (Pro-partner)	Subsidiary	The Company's subsidiary
GRAPE KING INTERNATIONAL INVESTMENT INC (BVI)	Subsidiary	The Company's subsidiary
Shanghai Grape King Enterprise Co., Ltd. (Shanghai Grape King)	Subsidiary	The Company's subsidiary
Shanghai Rivershine Ltd. (Shanghai Rivershine)	Subsidiary	The Company's subsidiary
Rivershine Ltd. (Rivershine)	Subsidiary	The Company's subsidiary
Shanghai Pujun Trading Co., Ltd. (Shanghai Pujun)	Subsidiary	The Company's subsidiary
PUBAI LIMITED (PUBAI)	Subsidiary	The Company's subsidiary
Shanghai Puxun Supply Chain Management Co., Ltd.	Subsidiary	The Company's subsidiary
Shanghai Puyou Trading Co., Ltd.	Subsidiary	The Company's subsidiary
Shanghai Puguang Trading Co., Ltd.	Subsidiary	The Company's subsidiary
ELITE PROPARTNER HOLDINGS SDN. BHD.	Subsidiary	The Company's subsidiary
UVACO MY SDN. BHD.	Subsidiary	The Company's subsidiary
MYGK BIO SDN. BHD.	Subsidiary	The Company's subsidiary
Lifeshine Co., Ltd (Lifeshine)	Substantive related party	Substantive related party

(Continued)

Related Party Name	Related Party Category	Relationship with the Company
Pu Hsing Enterprise Co., Ltd. (Pu Hsing)	Other related party	Director of Pro-partner
Uni-President Enterprises Corp. (Uni-President)	Other related party	Director of the Company
President Pharmaceutical Corp. (President Pharmaceutical)	Other related party	Subsidiary of a director of the Company
President Transnet Corp. (President Transnet)	Other related party	Subsidiary of a director of the Company
President Collect Services Corp. (President Collect Services)	Other related party	Subsidiary of a director of the Company
Presco Netmarketing, Inc. (Presco Netmarketing)	Other related party	Subsidiary of a director of the Company
Tong-Yo Co., Ltd. (Tong-Yo)	Other related party	Subsidiary of a director of the Company
RSI, Retail Support International Corp. (Retail Support)	Other related party	Subsidiary of a director of the Company
Tung-Bo Enterprise Corp. (Tung-Bo)	Other related party	Subsidiary of a director of the Company
Xin-Tung Enterprise Corp. (Xin-Tung)	Other related party	Subsidiary of a director of the Company
Tong-Yeen Enterprise Corp. (Tong-Yeen)	Other related party	Subsidiary of a director of the Company
Wei-Tong Enterprise Corp. (Wei-Tong)	Other related party	Subsidiary of a director of the Company
Presicarre Corp. (Presicarre)	Other related party	Subsidiary of a director of the Company
Yahoo! Taiwan Holdings Ltd.(Yahoo)	Other related party	Subsidiary of a director of the Company
Duskin Serve Taiwan Co., Ltd. (Duskin Serve Taiwan)	Other related party	Subsidiary of a director of the Company
GK BIO INTERNATIONAL SDN. BHD.	Associate	Investee of the Company accounted for using the equity method

(Concluded)

b. Sales of goods

Line Item	Related Party Category/Name	For the Year Ended December 31	
		2025	2024
Sales	Pro-partner	\$ 1,567,673	\$ 1,736,294
	Subsidiary	245,837	284,498
	Associate	42,480	50,853
	Other related party	<u>28,673</u>	<u>31,241</u>
		<u>\$ 1,884,663</u>	<u>\$ 2,102,886</u>

The sales price for the related parties and the price for the third-party MLM member customers were determined based on mutual consent. There is no significant difference regarding the terms and conditions for the related parties and the third parties.

c. Contract liabilities

Line Item	Related Party Category/Name	December 31	
		2025	2024
Contract liabilities	Other related party	\$ <u>1,009</u>	\$ <u>155</u>

d. Receivables from related parties

Line Item	Related Party Category/Name	December 31	
		2025	2024
Accounts receivable from related parties	Rivershine	\$ 115,850	\$ 120,959
	Pro-partner	70,358	154,943
	Subsidiary	7,396	4,127
	Associate	10,002	8,485
	Other related party	<u>3,779</u>	<u>6,327</u>
		<u>\$ 207,385</u>	<u>\$ 294,841</u>
Other receivables from related parties (including bonus to directors)	Pro-partner	\$ <u>74,040</u>	\$ <u>83,879</u>

e. Payables to related parties

Line Item	Related Party Category/Name	December 31	
		2025	2024
Other payables to related parties	Presco Netmarketing	\$ 2,790	\$ -
	Yahoo	423	392
	Retail Support	416	618
	President Transnet	391	526
	Other related party	<u>-</u>	<u>180</u>
		<u>\$ 4,020</u>	<u>\$ 1,716</u>

f. Prepayments

Line Item	Related Party Category/Name	December 31	
		2025	2024
Prepayments	Associate	\$ 203	\$ 203
	Other related party	<u>104</u>	<u>198</u>
		<u>\$ 307</u>	<u>\$ 401</u>

g. Lease arrangements

Line Item	Related Party Category/Name	December 31	
		2025	2024
Lease liabilities	Substantive related party	\$ <u>2,180</u>	\$ <u>3,353</u>

Related Party Category	For the Year Ended December 31	
	2025	2024
<u>Interest expense</u>		
Substantive related party	\$ <u>28</u>	\$ <u>40</u>

The rental paid to the above related party is similar to general market rental prices, and the rental is paid via remittance once a month.

h. Other transactions with related parties

Line Item	Related Party Category/Name	December 31	
		2025	2024
Guarantee deposits received	Pro-partner	\$ <u>558</u>	\$ <u>472</u>

Line Item	Related Party Category/Name	For the Year Ended December 31	
		2025	2024
Operating cost - inspection expense	Other related party	\$ <u>17</u>	\$ <u>25</u>
Operating cost - freight expense	Other related party	\$ <u>27</u>	\$ <u>20</u>
Selling and marketing expenses - freight expense	Other related party	\$ <u>3,867</u>	\$ <u>4,540</u>
Selling and marketing expenses - advertisement expense	Other related party	\$ <u>8,783</u>	\$ <u>1,165</u>
Selling and marketing expenses -other expense	Other related party	\$ <u>134</u>	\$ <u>52</u>
General and administrative expenses - freight expense	Other related party	\$ <u>8</u>	\$ <u>11</u>
Research and development expenses - inspection expense	Other related party	\$ <u>311</u>	\$ <u>467</u>
Research and development expenses - advertisement expense	Associate	\$ <u>-</u>	\$ <u>262</u>
Research and development expenses - freight expense	Other related party	\$ <u>90</u>	\$ <u>91</u>
Rental income	Pro-partner	\$ 2,855	\$ 2,854
	Rivershine	400	400
	Other related party	<u>11</u>	<u>11</u>
		\$ <u>3,266</u>	\$ <u>3,265</u>
Other income	Pro-partner	\$ <u>75,469</u>	\$ <u>84,530</u>

The terms and conditions of the above-mentioned related party transactions are similar to those of general non-related parties, and rental prices are similar to those of general transactions. The term of collection was either in monthly installments or in full at the beginning of each year.

i. Remuneration of key management personnel

	For the Year Ended December 31	
	2025	2024
Short-term employee benefits	\$ 53,853	\$ 61,898
Post-employment benefits	<u>259</u>	<u>258</u>
	<u>\$ 54,112</u>	<u>\$ 62,156</u>

The remuneration of directors and key executives, as determined by the remuneration committee, was based on the performance of individuals and market trends.

29. ASSETS PLEDGED AS COLLATERAL OR FOR SECURITY

The following assets were provided as collateral for long-term and short-term secured loans, Chinese Petroleum Corporation natural gas, Shin-Tao Natural Gas Corp., leasing land and operating center from science-based parks:

	December 31	
	2025	2024
Property, plant and equipment - land	\$ 1,249,843	\$ 1,249,843
Property, plant and equipment - building	201,508	204,557
Pledged time deposits (classified as financial assets at amortized cost - non-current)	<u>10,800</u>	<u>9,600</u>
	<u>\$ 1,462,151</u>	<u>\$ 1,464,000</u>

Secured bank facilities used in response to operating funds by the Company's property, plant and equipment - land/building as of December 31, 2025 and 2024 are as follows:

	December 31	
	2025	2024
Short-term financing facilities	\$ 238,000	\$ 238,000
Medium and long-term financing facilities	<u>450,000</u>	<u>450,000</u>
	<u>\$ 688,000</u>	<u>\$ 688,000</u>

30. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED COMMITMENTS

Significant contingencies and unrecognized commitments of the Company are as follows:

- a. The Company's guarantee notes issued to banks for credit lines amounted to NT\$100,000 thousand as of December 31, 2025.

- b. Details of significant constructions in progress and outstanding contracts of property, plant and equipment as of December 31, 2025 were as follows:

Nature of Contract	Contract Amount	Amount Paid	Outstanding Balance
Plant and machinery	<u>\$ 347,800</u>	<u>\$ 329,967</u>	<u>\$ 17,833</u>

31. SIGNIFICANT FINANCIAL ASSETS AND LIABILITIES DENOMINATED IN FOREIGN CURRENCIES

The Company's significant financial assets and liabilities denominated in foreign currencies aggregated by the foreign currencies other than functional currencies of the entities in the Company and the related exchange rates between the foreign currencies and the respective functional currencies were as follows:

December 31, 2025

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 4,016	31.430 (USD:NTD)	<u>\$ 126,235</u>
<u>Financial liabilities</u>			
Monetary items			
USD	218	31.430 (USD:NTD)	<u>\$ 6,839</u>

December 31, 2024

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 2,759	32.785 (USD:NTD)	<u>\$ 90,467</u>
<u>Financial liabilities</u>			
Monetary items			
USD	538	32.785 (USD:NTD)	<u>\$ 17,626</u>

For the years ended December 31, 2025 and 2024, realized and unrealized net foreign exchange gains were NT\$848 thousand and NT\$3,233 thousand, respectively. It is impractical to disclose net foreign exchange gains (losses) by each significant foreign currency due to the variety of the foreign currency transactions and functional currencies of the entities in the Company.

32. SEPARATELY DISCLOSED ITEMS

- a. Information about significant transactions:
 - 1) Financings provided to others: None;
 - 2) Endorsements/guarantees provided: None;
 - 3) Significant marketable securities held (excluding investments in subsidiaries, associates and jointly controlled entities): None.
 - 4) Total purchases from or sales to related parties of at least NT\$100 million or 20% of the paid-in capital: Table 1.
 - 5) Receivables from related parties amounting to at least NT\$100 million or 20% of the paid-in capital: Table 2.
- b. Information on investees: Table 3;
- c. Information on investment in mainland China
 - 1) The name of the investee in mainland China, the main businesses and products, its issued capital, method of investment, information on inflow or outflow of capital, percentage of ownership, net income (losses) of the investee, investment income (losses), ending balance, amount received as dividends from the investee, and the limitation on investee: Table 4
 - 2) Significant direct or indirect transactions with the investee, its prices and terms of payment and unrealized gain or loss: None

33. SEGMENTS INFORMATION

The Company has disclosed its operating segments in the consolidated financial statements.

GRAPE KING BIO LTD.

TOTAL PURCHASES FROM OR SALES TO RELATED PARTIES AMOUNTING AT LEAST NT\$100 MILLION OR 20% OF THE PAID-IN CAPITAL FOR THE YEAR ENDED DECEMBER 31, 2025
(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Company Name	Related Party	Nature of Relationship	Transaction Details				Abnormal Transaction (Note)		Notes/Accounts Payable or Receivable		Note
			Purchases/Sales	Amount	% to Total	Payment Terms	Unit Price	Payment Terms	Ending Balance	% to Total	
Grape King Bio Ltd.	Pro-partner Ltd.	Subsidiary	Sales	\$ 1,567,673	54.94%	30 days after monthly closing	By contract	-	\$ 70,358	20.20%	Note 2
Grape King Bio Ltd.	Rivershine Ltd.	Subsidiary	Sales	238,433	8.36%	120 days after monthly closing	By contract	-	115,850	33.25%	Note 2
Pro-partner Ltd.	Grape King Bio Ltd.	Parent company	Purchases	1,567,673	95.71%	30 days after monthly closing	By contract	-	(70,358)	91.57%	Note 2
Rivershine Ltd.	Grape King Bio Ltd.	Parent company	Purchases	238,433	100.00%	120 days after monthly closing	By contract	-	(115,850)	100%	Note 2

Note: If the terms of transactions with the related parties are different from normal terms, the difference and the reason for the difference should be declared in the column of unit price or credit period.

GRAPE KING BIO LTD.

**RECEIVABLES FROM RELATED PARTIES AMOUNTING TO AT LEAST NTS100 MILLION OR 20% OF THE PAID-IN CAPITAL
DECEMBER 31, 2025
(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)**

Company Name	Related Party	Nature of Relationship	Ending Balance	Turnover Days	Overdue		Amounts Received in Subsequent Period	Allowance for Bad Debts
					Amount	Action Taken		
Grape King Bio Ltd.	Rivershine Ltd.	Subsidiary	\$ 115,850	2.01	\$ -	-	\$ 24,991	\$ -

GRAPE KING BIO LTD.

INFORMATIONS ON INVESTEEES

FOR THE YEAR ENDED DECEMBER 31, 2025

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of December 31, 2025			Net Income (Losses) of the Investee	Investment Income (Losses)	Note	
				December 31, 2025	December 31, 2024	Shares	Percentage of Ownership (%)	Carrying Amount				
Grape King Bio Ltd.	GRAPE KING INTERNATIONAL INVESTMENT INC. Pro-partner Ltd.	BVI	Investment activities	\$ 1,198,018	\$ 1,198,018	24,890,000	100	\$ 1,166,446	\$ (25,260)	\$ (25,731)	Notes 1, 2 and 3	
		Taoyuan, Taiwan	Importing and selling of health food, drink, cosmetics, sports apparatus, cleaning products, etc.	15,000	15,000	10,560,000	60	2,441,862	1,614,191	973,858	Notes 1 and 2	
	Rivershine Ltd.	Taoyuan, Taiwan	Importing and selling of health food, drinks, daily cosmetics, appliances, etc.	30,000	30,000	3,000,000	100	52,187	13,660	13,660	Note 2	
	MYGK BIO SDN. BHD.	Malaysia	Selling of health products	10,982	-	1,500,000	100	10,187	(982)	(982)	Notes 2 and 6	
	GK BIO INTERNATIONAL SDN. BHD.	Malaysia	Importing and selling of health products	14,899	14,899	2,100,000	35	113,492	83,042	28,939	Note 1	
	Pro-partner Ltd.	ELITE PROPARTNER HOLDING SDN. BHD.	Malaysia	Selling of health products	7,425	7,425	1,000,000	100	6,059	(393)	Note 4	Note 2
		UVACO MY SDN. BHD.	Malaysia	Selling of health products	69,675	7,348	9,375,000	75	63,917	(7,093)	Note 4	Notes 2 and 7
Shanghai Grape King Enterprise Co., Ltd.	PUBAI LIMITED	Hong Kong	Selling of health products	-	-	550,000	55	2,111	-	Note 4	Notes 1, 2 and 5	

Note 1: The effect from the unrealized profit of the downstream transactions on income tax, which is NT\$ 4,826 thousand has been adjusted.

Note 2: The book value at the end of the period and the current investment gain (loss) recognized have been eliminated in the consolidated financial statements.

Note 3: The current investment gain (loss) recognized by BVI includes the current profit of Shanghai Grape King and Shanghai Rivershine.

Note 4: The share of profits/losses of the investee company is not reflected herein, as such amounts are already included in the share of profits/losses of the investor company.

Note 5: The Company invested in PUBAI LIMITED through subsidiary Shanghai Grape King Enterprise Co., Ltd. As of December 31, 2024, the capital has not been actually invested.

Note 6: The Company made an additional investment to establish MYGK BIO SDN. BHD. in Malaysia in January 2025.

Note 7: The subsidiary Pro-partner Ltd. increased its investment in UVACO MY SDN. BHD. by MYR 4,000 thousand in February 2025 and MYR 4,375 thousand in April 2025. In addition, during 2025, Pro-partner Ltd. did not participate in UVACO MY SDN. BHD.'s cash capital increase in proportion to its shareholding, resulting in a decrease in its ownership interest to 75%.

TABLE 5

GRAPE KING BIO LTD.

INFORMATION ON INVESTMENTS IN MAINLAND CHINA
FOR THE YEAR ENDED DECEMBER 31, 2025
(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Investee Company	Main Businesses and Products	Total Amount of Paid-in Capital	Method of Investment (Note 1)	Accumulated Outflow of Investment from Taiwan as of January 1, 2025	Investment Flows		Accumulated Outflow of Investment from Taiwan as of December 31, 2025	Net Income (Losses) of the Investee Company	Percentage of Ownership	Investment Income (Losses) (Note 2)	Carrying Amount as of December 31, 2025	Accumulated Inward Remittance of Earnings as of December 31, 2025
					Outflow	Inflow						
Shanghai Grape King Enterprise Co., Ltd.	Manufacturing and selling of capsules, tablets, related products and technical services. Warehousing services (excluding dangerous goods), cosmetics wholesale, domestic cargo transportation agency.	USD 28,900	Note 1(2) Note 3	\$ 847,672 (USD 27,350)	\$ -	\$ -	\$ 847,672 (USD 27,350)	\$ (23,642) Note 2(2)B	100%	\$ (24,039) Note 2(2)B	\$ 1,110,588	\$ -
Shanghai Rivershine Ltd.	Sale of food; transporting road cargo (excluding dangerous goods); wholesale of edible agricultural products; retail of edible agricultural products; sale of agricultural and sideline products; marketing planning; brand management; project planning and public relations services; information consulting services (excluding licensing information consulting services), etc.	USD 650	Note 1(2) Note 4	18,290 (USD 650)	-	-	18,290 (USD 650)	(625) Note 2(2)B	100%	(742) Note 2(3)	17,760 Note 2(3)	-
Shanghai Pujun Trading Co., Ltd.	Manufacturing and selling of capsules, tablets, related products and technical services. Warehousing services (excluding dangerous goods), cosmetics wholesale, domestic cargo transportation agency.	RMB 2,000	Note 1(2) Note 7	-	-	-	-	1,849 Note 2(2)B	51%	943 Note 2(2)B and 11	29,262	-
Shanghai Puxun Supply Chain Management Co., Ltd.	Supply chain management services; network technology services; technical services; technology development; technical consulting, etc.	RMB 1,000	Note 1(2) Note 8	-	-	-	-	94 Note 2(2)B	67%	63 Note 2(2)B	2,462	-
Shanghai Puyou Trading Co., Ltd.	Wholesale of edible agricultural products; retail of edible agricultural products; sale of agricultural and sideline products; marketing planning; brand management; vending machine sales, etc.	RMB 2,000	Note 1(2) Note 9	-	-	-	-	3,585 Note 2(2)B	61%	2,187 Note 2(2)B	8,207	-
Shanghai Puguang Trading Co., Ltd.	Wholesale of edible agricultural products; retail of edible agricultural products; sale of agricultural and sideline products; marketing planning; brand management; vending machine sales, etc.	RMB 2,000	Note 1(2) Note 10	-	-	-	-	2,364 Note 2(2)B	51%	1,206 Note 2(2)B	5,856	-

(Continued)

Investee Company	Main Businesses and Products	Total Amount of Paid-in Capital	Method of Investment (Note 1)	Accumulated Outflow of Investment from Taiwan as of January 1, 2025	Investment Flows		Accumulated Outflow of Investment from Taiwan as of December 31, 2025	Net Income (Losses) of the Investee Company	Percentage of Ownership	Investment Income (Losses) (Note 2)	Carrying Amount as of December 31, 2025	Accumulated Inward Remittance of Earnings as of December 31, 2025
					Outflow	Inflow						
Shanghai Changhong Biotechnology Co., Ltd.	Biotechnology consultation, biotechnology R&D and transfer, import and export of goods or transfers of technology, brand planning, corporate image and marketing planning, conference services, social and economic consulting services, business information consulting, self-owned equipment leasing, domestic cargo transportation agent, sales and online retail of knitted textiles, etc.	USD 700	Note 1(1) Note 5	\$ 7,273 (USD 246)	\$ -	\$ 7,273 (USD 246)	\$ -	\$ - Note 5	\$ - Note 5	\$ - Note 5	\$ - Note 5	\$ 315 (USD 10) Note 5
Shanghai Xinquan Biotechnology Co., Ltd.	Biotechnology technical technology development, consultation, service and transfer, sales of cosmetic and daily necessities, etc.	RMB 5,000	Note 1(2) Note 6	-	-	-	-	(492) Note 2(2)B	45%	(222) Note 2(2)B	- Note 6	-

Accumulated Investment in Mainland China as of December 31, 2025	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment
\$ 865,962	\$ 865,962	\$ 7,239,831

Note 1: The methods for engaging in investment in mainland China include the following:

- 1) Direct investment in mainland China.
- 2) Indirect investment in mainland China through companies registered in a third region (specify the name of the company in third region).
- 3) Other methods.

Note 2: The investment income (loss) recognized in current period:

1. No investment income (loss) has been recognized due to the investment is still in the development stage.
2. The investment income (loss) was determined based on the following basis:
 - (A) The financial report was reviewed and certified by an international accounting firm in cooperation with an accounting firm in the ROC.
 - (B) The financial statements were reviewed by the parent company's auditors.
3. Recorded as financial assets at fair value through other comprehensive income.

Note 3: The Company invested in Shanghai Grape King Enterprise Co., Ltd. through subsidiary GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI).

Note 4: The Company indirectly invested in Shanghai Rivershine Ltd. through its subsidiary, GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI).

Note 5: The Company directly invested in Shanghai Changhong Biotechnology Co., Ltd. completed its liquidation in August 2025, remitted the investment funds back to the Company in September 2025, and the case was filed with the Investment Commission for record on October 14, 2025.

Note 6: The Company invested in Shanghai Xinquan Biotechnology Co., Ltd. through its subsidiary Shanghai Rivershine Ltd., and Shanghai Xinquan Biotechnology Co., Ltd. completed its liquidation in June 2025.

Note 7: The Company invested in Shanghai Pujun Trading Co., Ltd. through subsidiary Shanghai Grape King Enterprise Co., Ltd..

Note 8: The Company invested in Shanghai Puxun Supply Chain Management Co., Ltd. through subsidiary Shanghai Grape King Enterprise Co., Ltd..

Note 9: The Company invested in Shanghai Puyou Trading Co.,Ltd. through subsidiary Shanghai Grape King Enterprise Co.,Ltd. and Shanghai Pujun Trading Co., Ltd..

Note 10: The Company invested in Shanghai Puguang Trading Co., Ltd. through subsidiary Shanghai Grape King Enterprise Co.,Ltd..

Note 11: The current investment gain (loss) recognized by Shanghai Grape King Enterprise Co., Ltd. includes the current profit of Shanghai Pujun, Shanghai Puxun, PUBAI, Shanghai Puyou, and Shanghai Puguang recognized based on the shareholding ratio.

Note 12: The current investment gain (loss) recognized by Shanghai Pujun Trading Co., Ltd. includes the current profit of Shanghai Puyou recognized based on the shareholding ratio.

(Concluded)

THE CONTENTS OF STATEMENTS OF MAJOR ACCOUNTING ITEMS

ITEM	STATEMENT INDEX
MAJOR ACCOUNTING ITEMS IN ASSETS, LIABILITIES AND EQUITY	
STATEMENT OF CASH AND CASH EQUIVALENTS	1
STATEMENT OF CHANGES IN FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME - NON-CURRENT	Note 7
STATEMENT OF CHANGES IN FINANCIAL ASSETS AT AMORTIZED COST	Note 8
STATEMENT OF NOTES AND ACCOUNTS RECEIVABLE, NET (RELATED PARTIES INCLUDED)	2
STATEMENT OF INVENTORIES, NET	3
STATEMENT OF CHANGES IN INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD	4
STATEMENT OF CHANGES IN PROPERTY, PLANT AND EQUIPMENT	Note 12
STATEMENT OF CHANGES IN ACCUMULATED DEPRECIATION OF PROPERTY, PLANT AND EQUIPMENT	Note 12
STATEMENT OF CHANGES IN INVESTMENT PROPERTIES	Note 14
STATEMENT OF CHANGES IN ACCUMULATED DEPRECIATION OF INVESTMENT PROPERTIES	Note 14
STATEMENT OF CHANGES IN RIGHT-OF-USE ASSETS	5
STATEMENT OF CHANGES IN ACCUMULATED DEPRECIATION OF RIGHT-OF-USE ASSETS	5
STATEMENT OF CHANGES IN INTANGIBLE ASSETS	Note 15
STATEMENT OF DEFERRED INCOME TAX ASSETS/LIABILITIES	Note 22
STATEMENT OF NOTES AND ACCOUNTS PAYABLE	6
STATEMENT OF OTHER ACCOUNTS PAYABLE	Note 17
STATEMENT OF LEASE LIABILITIES	7
MAJOR ACCOUNTING ITEMS IN PROFIT OR LOSS	
STATEMENT OF NET REVENUE	8
STATEMENT OF COST OF GOODS SOLD	9
STATEMENT OF SELLING AND MARKETING EXPENSES	10
STATEMENT OF GENERAL AND ADMINISTRATIVE EXPENSES	11
STATEMENT OF RESEARCH AND DEVELOPMENT EXPENSES	12
STATEMENT OF LABOR, DEPRECIATION AND AMORTIZATION BY FUNCTION	13

GRAPE KING BIO LTD.**STATEMENT OF CASH AND CASH EQUIVALENTS****DECEMBER 31, 2025****(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)**

Item	Description	Amount
Cash on hand		\$ 242
Deposits in banks		
Demand deposits		563,339
Foreign currency deposits	Including USD\$2,068 thousand @31.430, RMB\$1,349 thousand @4.496, JPY\$209 thousand @0.2008 and EUR\$1 thousand @36.900	71,177
Checking deposits		8
Cash equivalents		
Repurchase agreements collateralized by bonds	Expiring the end of by January 2026, interest rates 1.45%	400,000
Time deposits	Expiring the end of by March 2026, interest rates 3.35%-3.45%	<u>34,573</u>
Total		<u>\$ 1,069,339</u>

Note: Cash and cash equivalents were not pledged.

GRAPE KING BIO LTD.

STATEMENT OF NOTES AND ACCOUNTS RECEIVABLE, NET (RELATED PARTIES INCLUDED)

DECEMBER 31, 2025

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Client Name	Amount
Related Parties	
Rivershine Ltd.	\$ 115,850
Pro-partner Ltd.	70,358
GK BIO INTERNATIONAL SDN. BHD.	10,002
Shanghai Grape King Enterprise Co., Ltd.	4,407
PUBAI LIMITED	2,989
RSI, Retail Support International Corp.	1,505
Yahoo! Taiwan Holdings Ltd.	1,219
Uni-president Enterprises Corp	<u>1,055</u>
Total	<u>207,385</u>
Non-related parties	
T54990227	77,157
T42648698	14,341
T23224657	12,439
A00000097	8,086
Others (Note 1)	<u>28,972</u>
	140,995
Less: Loss allowance	-
Net	<u>140,995</u>
Total	<u>\$ 348,380</u>

Note 1: The amount of individual client included in others does not exceed 5% of the account balance.

Note 2: The accounts receivable incurred from operating activities were not pledged.

GRAPE KING BIO LTD.

**STATEMENT OF INVENTORIES, NET
DECEMBER 31, 2025**

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Item	<u>Amount</u>	
	Cost	Net Realizable Value
Raw materials	\$ 152,174	\$ 152,123
Supplies	65,773	63,452
Semi-finished goods and work in progress	246,973	246,808
Finished goods	236,229	508,694
Merchandises	<u>75</u>	<u>75</u>
Total	701,224	<u>\$ 971,152</u>
Less: Allowance for inventory valuation losses	<u>(6,627)</u>	
Net	<u>\$ 694,597</u>	

Note 1: Inventories are valued at lower of cost or net realizable value on an item-by-item basis.

Note 2: The insurance coverage for inventories was NT\$919,843 thousand as of December 31, 2025.

Note 3: Inventories were not pledged.

GRAPE KING BIO LTD.

STATEMENT OF CHANGES IN INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD
 FOR THE YEAR ENDED DECEMBER 31, 2025
 (Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Investee Companies	Balance, January 1, 2025		Additions in Investment		Decrease in Investment		Increase (Decrease) Investments Accounted for Using the Equity Method Amount (Note 1)	Balance, December 31, 2025			Net Assets Value	Collateral	Note
	Shares	Amount	Shares	Amount	Shares	Amount		Shares	%	Amount			
GRAPE KING INTERNATIONAL INVESTMENT INC.	24,890,000	\$ 1,186,542	-	\$ -	-	\$ -	\$ (20,096)	24,890,000	100	\$ 1,166,446	\$ 1,168,623	None	-
Pro-partner Ltd.	10,560,000	2,514,568	-	-	-	-	(72,706)	10,560,000	60	2,441,862	2,491,983	None	-
Rivershine Ltd.	3,000,000	57,741	-	-	-	-	(5,554)	3,000,000	100	52,187	52,187	None	-
MYGK BIO SDN. BHD.	-	-	1,500,000	10,982	-	-	(795)	1,500,000	100	10,187	10,187	None	-
GK BIO INTERNATIONAL SDN. BHD.	2,100,000	77,601	-	-	-	-	35,891	2,100,000	35	113,492	116,219	None	-
Shanghai Changhong Biotechnology Co., Ltd.	-	-	-	-	-	-	-	-	-	-	-	None	Note 2
Total		<u>\$ 3,836,452</u>		<u>\$ 10,982</u>		<u>\$ -</u>	<u>\$ (63,260)</u>			<u>\$ 3,784,174</u>	<u>\$ 3,839,199</u>		

Note 1: Mainly including share of profit or loss of subsidiaries and associates, share of other comprehensive income of subsidiaries and associates, cash dividends received from subsidiaries and associates, etc.

Note 2: Shanghai Changhong Biotechnology Co., Ltd. completed its liquidation procedures in August 2025.

GRAPE KING BIO LTD.

STATEMENT OF CHANGES IN RIGHT-OF-USE ASSETS AND CHANGES IN ACCUMULATED DEPRECIATION OF RIGHT-OF-USE ASSETS FOR THE YEAR ENDED DECEMBER 31, 2025
(In Thousands of New Taiwan Dollars, Unless Specified Otherwise)

	Land	Buildings	Transport- ation Equipment	Other Equipment	Total
Cost					
Balance at January 1, 2025	\$ 58,282	\$ 80,153	\$ 9,396	\$ 689	\$ 148,520
Additions	1,642	13,382	430	943	16,397
Disposals	<u>(1,490)</u>	<u>-</u>	<u>(989)</u>	<u>-</u>	<u>(2,479)</u>
Balance at December 31, 2025	<u>58,434</u>	<u>93,535</u>	<u>8,837</u>	<u>1,632</u>	<u>162,438</u>
Accumulated depreciation					
Balance at January 1, 2025	11,346	26,065	4,532	350	42,293
Depreciation Expenses	2,301	18,725	2,062	278	23,366
Disposals	<u>(1,490)</u>	<u>-</u>	<u>(989)</u>	<u>-</u>	<u>(2,479)</u>
Balance at December 31, 2025	<u>12,157</u>	<u>44,790</u>	<u>5,605</u>	<u>628</u>	<u>63,180</u>
Carrying amount at December 31, 2025	<u>\$ 46,277</u>	<u>\$ 48,745</u>	<u>\$ 3,232</u>	<u>\$ 1,004</u>	<u>\$ 99,258</u>

GRAPE KING BIO LTD.

STATEMENT OF NOTES AND ACCOUNTS PAYABLE

DECEMBER 31, 2025

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Name	Amount
89816787	\$ 45,541
24829752	16,586
Others (Note)	<u>258,612</u>
	<u>\$ 320,739</u>

Note: The amount of individual client included in others does not exceed 5% of the account balance, and all are non-related party payments.

GRAPE KING BIO LTD.

STATEMENT OF LEASE LIABILITIES

DECEMBER 31, 2025

(In Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Description	Lease Period	Discount Rate	December 31, 2025
Land	2016.04.15-2051.04.14	1.84%-1.96%	\$ 46,942
Buildings	2022.11.16-2029.12.31	1.02%-1.96%	50,453
Transportation equipment	2021.10.05-2028.05.31	1.02%-1.96%	3,298
Other equipment	2021.03.01-2030.07.31	1.02%-1.96%	<u>1,010</u>
Total			101,703
Less: Current portion			<u>(22,916)</u>
Noncurrent portion			<u>\$ 78,787</u>

GRAPE KING BIO LTD.**STATEMENT OF NET REVENUE****FOR THE YEAR ENDED DECEMBER 31, 2025****(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)**

Item	Quantity (In Thousands)	Amount
Sales revenue		
Health food	Note	\$ 1,871,706
ODM/OEM	Note	720,485
Beverage	Note	209,413
Cosmetics	Note	46,849
Others		<u>4,856</u>
 Total net revenue		 <u>\$ 2,853,309</u>

Note: Due to the wide variety and complexity of the products sold by the Company, it is difficult to count and classify.

GRAPE KING BIO LTD.

STATEMENT OF COST OF GOODS SOLD
 FOR THE YEAR ENDED DECEMBER 31, 2025
 (Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Item	Amount
Raw materials used	
Beginning balance	\$ 143,597
Add: Raw materials purchased	608,342
Less: Ending balance	(152,174)
Raw material shortage	(199)
Raw materials scrapped	(1,810)
Raw materials sold directly	(14,054)
Transferred to other accounts	(9,213)
Other operating costs	(6)
Direct materials used	<u>574,483</u>
Supplies used	
Beginning balance	67,024
Add: Supplies purchased	297,851
Gain from supplies physical counts	524
Less: Ending balance	(65,773)
Supplies sold directly	(1,406)
Supplies scrapped	(1,032)
Transferred to other accounts	(50,794)
Supplies used	<u>246,340</u>
Direct labor	129,650
Manufacturing overhead	<u>454,774</u>
Manufacturing cost	<u>1,405,247</u>
Semi-finished goods and work in process	
Beginning balance	235,173
Add: Gain from semi-finished goods physical counts	1,108
Other operating costs	38,562
Less: Ending balance	(246,974)
Semi-finished goods and work in process scrapped	(4,573)
Transferred to other accounts	(61,054)
Semi-finished goods sold directly	<u>(43,228)</u>
Cost of finished goods	1,324,261
Add: Beginning balance	225,174
Finished goods purchased	174,181
Transferred from other accounts	38,355
Other operating costs	572,186
Less: Ending balance	(236,229)
Inventory shortage - finished goods	(418)
Finished goods scrapped	<u>(3,394)</u>
Cost of goods sold at normal production level	<u>2,094,16</u>
Merchandise cost	
Beginning balance	82
Add: Merchandise purchased	2
Less: Ending balance	(75)
Transferred to other accounts	<u>(4)</u>
Cost of merchandise sold	<u>5</u>
Cost of raw materials sold directly	1,259
Cost of supplies sold directly	1,460
Cost of semi-finished goods sold directly	51,664
Transferred to other accounts	(679,726)
Gain (loss) from physical counts	(1,015)
Scrapped	10,809
Other operating costs	<u>170,706</u>
Total	<u>\$ 1,649,278</u>

GRAPE KING BIO LTD.**STATEMENT OF SELLING AND MARKETING EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2025
(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)**

Item	Amount
Advertising	\$ 199,346
Salaries and wages	85,866
Depreciation	37,546
Tax	24,218
Others (Note)	<u>59,313</u>
Total	<u>\$ 406,289</u>

Note: Expenses included in others do not exceed 5% of the account balance.

GRAPE KING BIO LTD.

**STATEMENT OF GENERAL AND ADMINISTRATIVE EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2025**

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Item	Amount
Salaries and wages	\$ 161,804
Depreciation	33,670
Labor costs	28,579
Amortization of various items	21,554
Others (Note)	<u>120,404</u>
Total	<u>\$ 366,011</u>

Note: Expenses included in others do not exceed 5% of the account balance.

GRAPE KING BIO LTD.

**STATEMENT OF RESEARCH AND DEVELOPMENT EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2025**

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Item	Amount
Salaries and wages	\$ 90,069
Research experiment fee	51,929
Depreciation	17,105
Commissioned research fee	16,622
Others (Note)	<u>63,600</u>
Total	<u>\$ 239,325</u>

Note: Expenses included in others do not exceed 5% of the account balance.

GRAPE KING BIO LTD.

STATEMENT OF LABOR, DEPRECIATION AND AMORTIZATION BY FUNCTION
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

	For the Year Ended December 31					
	2025			2024		
	Cost of Goods Sold	Operating Expenses	Total	Cost of Goods Sold	Operating Expenses	Total
Employee benefits expense						
Salaries and wages	\$ 195,348	\$ 297,993	\$ 493,341	\$ 179,460	\$ 329,091	\$ 568,551
Labor and health insurance	20,863	21,403	42,266	19,805	22,664	42,469
Pension	7,844	8,498	16,342	7,744	7,983	15,727
Other employee benefits	11,789	8,301	20,090	11,562	8,548	20,110
Board compensation	-	31,248	31,248	-	37,147	37,147
	<u>\$ 235,844</u>	<u>\$ 367,443</u>	<u>\$ 603,287</u>	<u>\$ 218,571</u>	<u>\$ 405,433</u>	<u>\$ 624,004</u>
Depreciation (Note 2)	<u>\$ 273,616</u>	<u>\$ 88,588</u>	<u>\$ 362,204</u>	<u>\$ 240,703</u>	<u>\$ 91,114</u>	<u>\$ 331,817</u>
Amortization	<u>\$ 1,647</u>	<u>\$ 27,079</u>	<u>\$ 28,726</u>	<u>\$ 897</u>	<u>\$ 22,163</u>	<u>\$ 23,060</u>

Note 1: For the years of 2025 and 2024, the Company had an average of 583 and 575 employees, respectively, which included 10 non-employee directors for both of the years ended December 31, 2025 and 2024.

- 1) Average labor costs for the years ended December 31, 2025 and 2024 were NT\$998 thousand and NT\$1,039 thousand, respectively.
- 2) Average salaries and bonuses for the years ended December 31, 2025 and 2024 were NT\$861 thousand and NT\$900 thousand, respectively.
- 3) The average salary and bonus decreased by (4.33)% year over year.
- 4) Compensation policies

A. Directors and Managers

The remuneration shall be paid to directors who manage the Company's business. The amount is determined based on the directors' participation in the Company operations and value of contribution. In accordance with the Articles of Incorporation, the Board of Directors is authorized to provide compensation based on industry standards. In case of profit generated for the year, it shall set aside no more than 2% for the remuneration of directors as stipulated in the Articles of Incorporation. The actual appropriation ratio and amount shall be proposed by the Remuneration Committee based on operational performance and submitted to the Board of Directors for resolution. As for independent directors not included in the Company's profit distribution, the executive compensation shall be paid based on a fixed amount and requires a Board of Directors resolution.

The remuneration of managers is determined based on individual performance, contribution to the Company's overall operations and market standards. In addition, if there is profit generated for the year, 6%-8% shall be set aside for employee compensation, which also includes managerial remuneration as stipulated in the Articles of Incorporation, and shall be proposed by the Remuneration Committee based on operational performance and submitted to the Board of Directors for approval.

(Continued)

The proposed remuneration of directors not included Independent Directors and managers shall be submitted to the Remuneration Committee for approval in accordance with the Articles of Incorporation and related regulations (as for the remuneration of independent directors, to avoid a conflict of interest, it is paid by the Board of Directors as stipulated in the Articles of Incorporation and according to industry standards, and is not determined by the Remuneration Committee).

B. Employees

The Company's assessment of salaries is determined based on the interview evaluation results at each stage, based on the rank of the employee. The compensation and bonus system are handled in accordance with the "Performance Appraisal Management Measures", which includes performance bonuses, year-end bonuses, and mid-year bonuses (compensation of employees). The performance bonus of the sales team is handled in accordance with the "performance bonus distribution method", and monthly bonuses and quarterly bonuses are issued based on the performance goals; employee year-end bonuses and mid-year bonuses (compensation of employees) are issued based on the Company's previous year's profit status, The number of employees and the results of the annual appraisal will be considered.

Note 2: The aforementioned depreciation expenses, including the depreciation of investment properties, were recognized by the Company under other gains and losses and amounted to NT\$267 thousand and NT\$266 thousand for the years ended December 31, 2025 and 2024, respectively.

(Concluded)